

				Overactive thyroid (E.1/E.1) <sup>1</sup>		Underactive thyroid (E.2/E.2) <sup>1</sup>		Thyroid nodules (E.3/E.3) <sup>1</sup>		Thyroid enlargement (E.4/E.4) <sup>1</sup>		Diabetes-diet (E.5/E.5) <sup>1</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		25658	456	1.8	2644	10.4	597	2.3	623	2.4	330	1.3
	Age at baseline	<18	5685	44	0.8	382	6.8	32	0.6	45	0.8	33	0.6
		18-19	2155	24	1.1	162	7.6	27	1.3	32	1.5	15	0.7
		20-24	6010	86	1.4	523	8.8	91	1.5	120	2.0	63	1.1
		25-29	5553	109	2.0	612	11.1	127	2.3	161	2.9	86	1.6
		30-34	3865	120	3.1	539	14.1	158	4.1	129	3.4	73	1.9
		35+	2390	73	3.1	426	18.0	162	6.9	136	5.7	60	2.5
	Years since diagnosis	5-9	2588	25	1.0	176	6.8	10	0.4	25	1.0	14	0.5
		10-14	8347	123	1.5	820	9.9	108	1.3	134	1.6	81	1.0
		15-19	8210	156	1.9	859	10.5	192	2.4	210	2.6	86	1.1
		20+	6513	152	2.4	789	12.2	287	4.5	254	3.9	149	2.3
	Age at diagnosis	<1	1926	13	0.7	105	5.5	17	0.9	17	0.9	24	1.3
		1-4	8262	94	1.1	618	7.5	116	1.4	136	1.7	71	0.9
		5-9	5782	102	1.8	592	10.3	132	2.3	150	2.6	70	1.2
		10-14	5444	134	2.5	644	11.9	168	3.1	167	3.1	88	1.6
		15-20	4244	113	2.7	685	16.2	164	3.9	153	3.6	77	1.8
	Treatment	Surgery only	2162	25	1.2	69	3.2	11	0.5	24	1.1	16	0.7
		Chemotherapy, no radiation	8136	75	0.9	301	3.7	78	1.0	114	1.4	97	1.2
		Radiation, no chemotherapy	2086	63	3.1	475	23.0	112	5.4	86	4.2	12	0.6
		Chemotherapy and radiation	10771	241	2.3	1605	15.0	356	3.3	355	3.3	176	1.6
		Unknown	2503	52	2.1	194	7.8	40	1.6	44	1.8	29	1.2
Males	All cases		13721	223	1.6	1213	8.9	175	1.3	217	1.6	136	1.0
	Age at baseline	<18	3062	33	1.1	224	7.4	15	0.5	24	0.8	15	0.5
		18-19	1125	8	0.7	91	8.1	14	1.3	14	1.3	9	0.8
		20-24	3164	40	1.3	260	8.3	28	0.9	39	1.2	23	0.7
		25-29	3085	59	1.9	292	9.5	46	1.5	64	2.1	33	1.1
		30-34	2056	46	2.3	203	9.9	38	1.9	41	2.0	29	1.4
		35+	1229	37	3.0	143	11.7	34	2.8	35	2.9	27	2.2
	Years since diagnosis	5-9	1453	10	0.7	94	6.5	5	0.3	11	0.8	5	0.3
		10-14	4469	69	1.6	413	9.3	40	0.9	58	1.3	32	0.7
		15-19	4317	72	1.7	378	8.8	53	1.2	74	1.7	34	0.8
		20+	3482	72	2.1	328	9.5	77	2.2	74	2.2	65	1.9
	Age at diagnosis	<1	983	6	0.6	56	5.7	5	0.5	6	0.6	14	1.4
		1-4	4326	51	1.2	328	7.6	45	1.1	52	1.2	32	0.7
		5-9	3261	56	1.7	316	9.8	49	1.5	58	1.8	26	0.8
		10-14	2880	54	1.9	272	9.5	37	1.3	47	1.6	28	1.0
		15-20	2271	56	2.5	241	10.7	39	1.7	54	2.4	36	1.6
	Treatment	Surgery only	1065	13	1.2	26	2.5	2	0.2	6	0.6	8	0.8
		Chemotherapy, no radiation	4287	35	0.8	115	2.7	18	0.4	29	0.7	42	1.0
		Radiation, no chemotherapy	1086	31	2.9	217	20.1	37	3.4	29	2.7	2	0.2
		Chemotherapy and radiation	5805	112	1.9	767	13.3	109	1.9	136	2.4	75	1.3
		Unknown	1478	32	2.2	88	6.0	9	0.6	17	1.2	9	0.6
Females	All cases		11937	233	2.0	1431	12.1	422	3.6	406	3.4	194	1.6
	Age at baseline	<18	2623	11	0.4	158	6.1	17	0.7	21	0.8	18	0.7
		18-19	1030	16	1.6	71	7.0	13	1.3	18	1.8	6	0.6
		20-24	2846	46	1.6	263	9.3	63	2.2	81	2.9	40	1.4

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems

n=7 participants with no baseline information are not included

				Diabetes-pills (E.6/E.6) <sup>1</sup>		Diabetes-insulin (E.7/E.7) <sup>1</sup>		Growth hormone deficiency (E.8/E.8) <sup>1</sup>		Osteoporosis (E.10/E.10) <sup>1</sup>		Any hormonal problem <sup>2</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		25658	266	1.1	398	1.6	1994	7.9	1190	4.7	5741	22.9
	Age at baseline	<18	5685	17	0.3	54	1.0	653	11.6	207	3.7	1037	18.5
		18-19	2155	9	0.4	20	0.9	243	11.6	109	5.1	430	20.6
		20-24	6010	44	0.7	86	1.4	560	9.6	284	4.8	1226	21.0
		25-29	5553	74	1.4	101	1.8	397	7.3	294	5.3	1318	24.4
		30-34	3865	58	1.5	76	2.0	113	3.0	187	4.9	985	26.3
		35+	2390	64	2.7	61	2.6	28	1.2	109	4.6	745	31.8
	Years since diagnosis	5-9	2588	8	0.3	43	1.7	210	8.3	110	4.3	468	18.5
		10-14	8347	39	0.5	113	1.4	710	8.7	399	4.8	1785	21.9
		15-19	8210	77	1.0	110	1.3	624	7.8	363	4.4	1815	22.7
		20+	6513	142	2.2	132	2.0	450	7.0	318	4.9	1673	26.4
	Age at diagnosis	<1	1926	9	0.5	21	1.1	132	6.9	51	2.7	264	13.9
		1-4	8262	72	0.9	82	1.0	967	11.9	337	4.1	1655	20.5
		5-9	5782	49	0.9	72	1.3	640	11.3	317	5.5	1351	24.0
		10-14	5444	65	1.2	132	2.4	221	4.2	307	5.7	1334	25.1
		15-20	4244	71	1.7	91	2.2	34	0.8	178	4.2	1137	27.7
	Treatment	Surgery only	2162	11	0.5	12	0.6	40	1.9	39	1.8	181	8.6
		Chemotherapy, no radiation	8136	79	1.0	115	1.4	182	2.3	333	4.1	1011	12.7
		Radiation, no chemotherapy	2086	21	1.1	20	1.0	283	14.2	86	4.2	805	40.2
		Chemotherapy and radiation	10771	135	1.3	213	2.0	1321	12.6	634	5.9	3271	31.2
		Unknown	2503	20	0.8	38	1.5	168	6.8	98	3.9	473	19.1
Males	All cases		13721	122	0.9	180	1.3	1183	8.8	516	3.8	2734	20.4
	Age at baseline	<18	3062	8	0.3	23	0.8	396	13.0	116	3.8	609	20.2
		18-19	1125	4	0.4	11	1.0	143	13.1	62	5.5	233	21.3
		20-24	3164	17	0.5	39	1.2	327	10.6	129	4.1	605	19.6
		25-29	3085	31	1.0	44	1.4	235	7.8	122	4.0	623	20.8
		30-34	2056	30	1.5	36	1.8	69	3.4	52	2.5	386	19.3
		35+	1229	32	2.7	27	2.2	13	1.1	35	2.9	278	23.1
	Years since diagnosis	5-9	1453	3	0.2	21	1.4	132	9.3	60	4.1	269	19.0
		10-14	4469	18	0.4	50	1.1	431	9.8	193	4.3	914	20.9
		15-19	4317	31	0.7	47	1.1	365	8.7	150	3.5	839	20.0
		20+	3482	70	2.0	62	1.8	255	7.4	113	3.3	712	21.0
	Age at diagnosis	<1	983	6	0.6	10	1.0	75	7.7	25	2.6	133	13.8
		1-4	4326	31	0.7	34	0.8	574	13.5	161	3.7	866	20.4
		5-9	3261	20	0.6	32	1.0	368	11.5	156	4.8	714	22.5
		10-14	2880	31	1.1	57	2.0	147	5.2	115	4.0	570	20.2
		15-20	2271	34	1.5	47	2.1	19	0.9	59	2.6	451	20.6
	Treatment	Surgery only	1065	6	0.6	7	0.7	27	2.6	20	1.9	86	8.3
		Chemotherapy, no radiation	4287	34	0.8	57	1.3	103	2.4	136	3.2	436	10.4
		Radiation, no chemotherapy	1086	10	1.0	6	0.6	151	14.5	36	3.3	377	36.3
		Chemotherapy and radiation	5805	61	1.1	95	1.6	785	13.8	283	4.9	1591	28.1
		Unknown	1478	11	0.7	15	1.0	117	8.0	41	2.8	244	16.7
Females	All cases		11937	144	1.2	218	1.8	811	6.9	674	5.7	3007	25.8
	Age at baseline	<18	2623	9	0.3	31	1.2	257	9.9	91	3.5	428	16.6
		18-19	1030	5	0.5	9	0.9	100	9.9	47	4.6	197	19.8
		20-24	2846	27	1.0	47	1.7	233	8.4	155	5.5	621	22.5

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included

				Overactive thyroid (E.1/E.1) <sup>1</sup>		Underactive thyroid (E.2/E.2) <sup>1</sup>		Thyroid nodules (E.3/E.3) <sup>1</sup>		Thyroid enlargement (E.4/E.4) <sup>1</sup>		Diabetes-diet (E.5/E.5) <sup>1</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
		25-29	2468	50	2.0	320	13.1	81	3.3	97	4.0	53	2.2
		30-34	1809	74	4.1	336	18.8	120	6.7	88	4.9	44	2.5
		35+	1161	36	3.1	283	24.6	128	11.1	101	8.8	33	2.9
	<b>Years since diagnosis</b>	5-9	1135	15	1.3	82	7.2	5	0.4	14	1.2	9	0.8
		10-14	3878	54	1.4	407	10.6	68	1.8	76	2.0	49	1.3
		15-19	3893	84	2.2	481	12.4	139	3.6	136	3.5	52	1.3
		20+	3031	80	2.7	461	15.4	210	7.0	180	6.0	84	2.8
	<b>Age at diagnosis</b>	<1	943	7	0.7	49	5.2	12	1.3	11	1.2	10	1.1
		1-4	3936	43	1.1	290	7.4	71	1.8	84	2.2	39	1.0
		5-9	2521	46	1.8	276	11.1	83	3.3	92	3.7	44	1.8
		10-14	2564	80	3.1	372	14.6	131	5.2	120	4.7	60	2.4
		15-20	1973	57	2.9	444	22.7	125	6.4	99	5.1	41	2.1
	<b>Treatment</b>	Surgery only	1097	12	1.1	43	3.9	9	0.8	18	1.6	8	0.7
		Chemotherapy, no radiation	3849	40	1.0	186	4.9	60	1.6	85	2.2	55	1.4
		Radiation, no chemotherapy	1000	32	3.3	258	26.2	75	7.6	57	5.8	10	1.0
		Chemotherapy and radiation	4966	129	2.6	838	17.0	247	5.0	219	4.5	101	2.0
		Unknown	1025	20	2.0	106	10.4	31	3.0	27	2.6	20	2.0

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included

			Diabetes-pills (E.6/E.6) <sup>1</sup>			Diabetes-insulin (E.7/E.7) <sup>1</sup>			Growth hormone deficiency (E.8/E.8) <sup>1</sup>			Osteoporosis (E.10/E.10) <sup>1</sup>			Any hormonal problem <sup>2</sup>		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		25-29	2468	43	1.8	57	2.3	162	6.7	172	7.0	695	28.9				
		30-34	1809	28	1.6	40	2.2	44	2.5	135	7.5	599	34.2				
		35+	1161	32	2.8	34	2.9	15	1.3	74	6.4	467	41.1				
	Years since diagnosis	5-9	1135	5	0.4	22	1.9	78	7.0	50	4.4	199	18.0				
		10-14	3878	21	0.5	63	1.6	279	7.3	206	5.4	871	23.0				
		15-19	3893	46	1.2	63	1.6	259	6.8	213	5.5	976	25.7				
		20+	3031	72	2.4	70	2.3	195	6.6	205	6.8	961	32.6				
	Age at diagnosis	<1	943	3	0.3	11	1.2	57	6.1	26	2.8	131	14.1				
		1-4	3936	41	1.1	48	1.2	393	10.2	176	4.5	789	20.6				
		5-9	2521	29	1.2	40	1.6	272	11.0	161	6.4	637	25.9				
		10-14	2564	34	1.4	75	2.9	74	3.0	192	7.6	764	30.6				
		15-20	1973	37	1.9	44	2.2	15	0.8	119	6.1	686	35.7				
	Treatment	Surgery only	1097	5	0.5	5	0.5	13	1.2	19	1.7	95	8.8				
		Chemotherapy, no radiation	3849	45	1.2	58	1.5	79	2.1	197	5.2	575	15.3				
		Radiation, no chemotherapy	1000	11	1.2	14	1.4	132	13.9	50	5.1	428	44.4				
		Chemotherapy and radiation	4966	74	1.5	118	2.4	536	11.1	351	7.1	1680	34.9				
		Unknown	1025	9	0.9	23	2.3	51	5.0	57	5.6	229	22.7				

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included

				Overactive thyroid (E.1/E.1) <sup>1</sup>		Underactive thyroid (E.2/E.2) <sup>1</sup>		Thyroid nodules (E.3/E.3) <sup>1</sup>		Thyroid enlargement (E.4/E.4) <sup>1</sup>		Diabetes-diet (E.5/E.5) <sup>1</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		7872	86	1.1	422	5.4	91	1.2	126	1.6	134	1.7
	Age at baseline	<18	2233	14	0.6	98	4.4	6	0.3	14	0.6	19	0.9
		18-19	844	6	0.7	44	5.3	9	1.1	13	1.6	10	1.2
		20-24	1964	20	1.0	111	5.7	22	1.1	29	1.5	21	1.1
		25-29	1598	25	1.6	90	5.7	26	1.6	38	2.4	41	2.6
		30-34	837	17	2.0	50	6.0	15	1.8	17	2.0	23	2.8
		35+	396	4	1.0	29	7.4	13	3.4	15	3.8	20	5.1
	Years since diagnosis	5-9	980	4	0.4	15	1.5	5	0.5	8	0.8	8	0.8
		10-14	2637	22	0.8	139	5.3	11	0.4	29	1.1	33	1.3
		15-19	2439	31	1.3	131	5.4	26	1.1	36	1.5	34	1.4
		20+	1816	29	1.6	137	7.6	49	2.7	53	2.9	59	3.3
	Age at diagnosis	<1	241	2	0.8	33	13.8	5	2.1	3	1.3	10	4.2
		1-4	3709	34	0.9	193	5.2	38	1.0	49	1.3	36	1.0
		5-9	1924	20	1.0	89	4.7	20	1.0	35	1.8	32	1.7
		10-14	1311	19	1.5	74	5.7	19	1.5	20	1.5	34	2.6
		15-20	687	11	1.6	33	4.8	9	1.3	19	2.8	22	3.2
	Treatment	Surgery only	3	.	.	.	.	.	.	.	.	.	.
		Chemotherapy, no radiation	3367	22	0.7	129	3.9	19	0.6	36	1.1	37	1.1
		Radiation, no chemotherapy	4	.	.	.	.	.	.	.	.	.	.
		Chemotherapy and radiation	3762	52	1.4	264	7.1	70	1.9	82	2.2	87	2.3
		Unknown	736	12	1.6	29	4.0	2	0.3	8	1.1	10	1.4
Males	All cases		4200	40	1.0	194	4.6	32	0.8	44	1.1	54	1.3
	Age at baseline	<18	1219	11	0.9	57	4.7	4	0.3	9	0.7	4	0.3
		18-19	455	1	0.2	28	6.2	2	0.4	5	1.1	6	1.3
		20-24	996	5	0.5	44	4.4	5	0.5	8	0.8	8	0.8
		25-29	867	16	1.9	40	4.6	11	1.3	13	1.5	21	2.4
		30-34	440	4	0.9	15	3.4	5	1.1	5	1.1	6	1.4
		35+	223	3	1.4	10	4.5	5	2.3	4	1.8	9	4.1
	Years since diagnosis	5-9	557	2	0.4	8	1.4	2	0.4	4	0.7	1	0.2
		10-14	1414	12	0.9	74	5.3	5	0.4	13	0.9	12	0.9
		15-19	1254	12	1.0	52	4.2	6	0.5	13	1.0	14	1.1
		20+	975	14	1.5	60	6.2	19	2.0	14	1.5	27	2.8
	Age at diagnosis	<1	112	1	0.9	16	14.4	2	1.8	.	.	6	5.4
		1-4	1985	16	0.8	98	5.0	14	0.7	19	1.0	16	0.8
		5-9	1038	10	1.0	49	4.8	7	0.7	11	1.1	9	0.9
		10-14	647	8	1.2	21	3.3	3	0.5	6	0.9	13	2.0
		15-20	418	5	1.2	10	2.4	6	1.4	8	1.9	10	2.4
	Treatment	Surgery only	1	.	.	.	.	.	.	.	.	.	.
		Chemotherapy, no radiation	1689	9	0.5	51	3.0	6	0.4	9	0.5	18	1.1
		Radiation, no chemotherapy	3	.	.	.	.	.	.	.	.	.	.
		Chemotherapy and radiation	2066	24	1.2	127	6.2	26	1.3	33	1.6	33	1.6
		Unknown	441	7	1.6	16	3.6	.	.	2	0.5	3	0.7
Females	All cases		3672	46	1.3	228	6.3	59	1.6	82	2.2	80	2.2
	Age at baseline	<18	1014	3	0.3	41	4.1	2	0.2	5	0.5	15	1.5
		18-19	389	5	1.3	16	4.2	7	1.8	8	2.1	4	1.0
		20-24	968	15	1.6	67	7.0	17	1.8	21	2.2	13	1.3

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems

n=7 participants with no baseline information are not included

				Diabetes-pills (E.6/E.6) <sup>1</sup>		Diabetes-insulin (E.7/E.7) <sup>1</sup>		Growth hormone deficiency (E.8/E.8) <sup>1</sup>		Osteoporosis (E.10/E.10) <sup>1</sup>		Any hormonal problem <sup>2</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		7872	97	1.3	213	2.7	547	7.1	463	5.9	1490	19.5
	Age at baseline	<18	2233	8	0.4	31	1.4	195	8.8	109	4.9	370	16.8
		18-19	844	5	0.6	11	1.3	90	11.0	57	6.8	168	20.7
		20-24	1964	12	0.6	48	2.5	139	7.3	105	5.4	349	18.4
		25-29	1598	35	2.2	60	3.8	98	6.3	109	6.9	350	22.5
		30-34	837	15	1.8	33	4.0	16	2.0	58	7.0	156	19.3
		35+	396	22	5.7	30	7.7	9	2.3	25	6.4	97	25.3
	Years since diagnosis	5-9	980	2	0.2	34	3.5	45	4.6	53	5.5	143	14.9
		10-14	2637	14	0.5	65	2.5	203	7.8	173	6.6	494	19.1
		15-19	2439	27	1.1	53	2.2	173	7.3	137	5.6	436	18.5
		20+	1816	54	3.0	61	3.4	126	7.1	100	5.6	417	23.7
	Age at diagnosis	<1	241	5	2.1	11	4.6	41	17.2	18	7.5	70	29.4
		1-4	3709	35	1.0	40	1.1	339	9.3	164	4.4	660	18.2
		5-9	1924	18	1.0	36	1.9	126	6.7	119	6.2	332	17.8
		10-14	1311	19	1.5	82	6.3	36	2.8	113	8.7	287	22.4
		15-20	687	20	3.0	44	6.4	5	0.8	49	7.2	141	21.3
	Treatment	Surgery only	3	.	.	.	.	.	.	.	.	.	.
		Chemotherapy, no radiation	3367	30	0.9	73	2.2	90	2.7	195	5.8	473	14.3
		Radiation, no chemotherapy	4	.	.	1	25.0	.	.	1	25.0	2	50.0
		Chemotherapy and radiation	3762	58	1.6	119	3.2	402	11.1	232	6.2	891	24.6
		Unknown	736	9	1.2	20	2.7	55	7.5	35	4.8	124	17.1
Males	All cases		4200	41	1.0	99	2.4	355	8.6	222	5.3	752	18.3
	Age at baseline	<18	1219	2	0.2	14	1.2	134	11.0	70	5.8	230	19.1
		18-19	455	3	0.7	6	1.3	61	13.8	34	7.5	99	22.4
		20-24	996	5	0.5	22	2.2	83	8.6	52	5.2	169	17.5
		25-29	867	14	1.6	27	3.1	64	7.5	44	5.1	159	18.8
		30-34	440	6	1.4	16	3.7	10	2.3	13	3.0	52	12.1
		35+	223	11	5.0	14	6.3	3	1.4	9	4.1	43	19.8
	Years since diagnosis	5-9	557	.	.	18	3.2	31	5.6	29	5.2	87	15.8
		10-14	1414	5	0.4	28	2.0	142	10.2	95	6.7	276	19.9
		15-19	1254	11	0.9	24	1.9	102	8.4	58	4.6	198	16.3
		20+	975	25	2.6	29	3.0	80	8.3	40	4.1	191	20.1
	Age at diagnosis	<1	112	2	1.8	4	3.6	25	22.7	11	10.0	35	31.8
		1-4	1985	16	0.8	20	1.0	224	11.5	95	4.8	366	18.8
		5-9	1038	5	0.5	16	1.6	80	7.9	62	6.0	177	17.6
		10-14	647	10	1.6	33	5.1	22	3.4	35	5.5	105	16.4
		15-20	418	8	2.0	26	6.2	4	1.0	19	4.5	69	17.1
	Treatment	Surgery only	1	.	.	.	.	.	.	.	.	.	.
		Chemotherapy, no radiation	1689	11	0.7	39	2.3	51	3.0	88	5.2	218	13.2
		Radiation, no chemotherapy	3	.	.	.	.	.	.	1	33.3	1	33.3
		Chemotherapy and radiation	2066	26	1.3	52	2.5	262	13.0	116	5.6	462	23.0
		Unknown	441	4	0.9	8	1.8	42	9.6	17	3.9	71	16.2
Females	All cases		3672	56	1.6	114	3.1	192	5.4	241	6.6	738	20.7
	Age at baseline	<18	1014	6	0.6	17	1.7	61	6.1	39	3.9	140	14.0
		18-19	389	2	0.5	5	1.3	29	7.7	23	6.0	69	18.6
		20-24	968	7	0.7	26	2.7	56	6.0	53	5.5	180	19.4

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included

				Overactive thyroid (E.1/E.1) <sup>1</sup>		Underactive thyroid (E.2/E.2) <sup>1</sup>		Thyroid nodules (E.3/E.3) <sup>1</sup>		Thyroid enlargement (E.4/E.4) <sup>1</sup>		Diabetes-diet (E.5/E.5) <sup>1</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
		25-29	731	9	1.2	50	6.8	15	2.1	25	3.4	20	2.7
		30-34	397	13	3.3	35	8.9	10	2.5	12	3.0	17	4.3
		35+	173	1	0.6	19	11.2	8	4.8	11	6.5	11	6.4
	Years since diagnosis	5-9	423	2	0.5	7	1.7	3	0.7	4	1.0	7	1.7
		10-14	1223	10	0.8	65	5.3	6	0.5	16	1.3	21	1.7
		15-19	1185	19	1.6	79	6.7	20	1.7	23	2.0	20	1.7
		20+	841	15	1.8	77	9.2	30	3.6	39	4.7	32	3.8
	Age at diagnosis	<1	129	1	0.8	17	13.3	3	2.3	3	2.3	4	3.1
		1-4	1724	18	1.1	95	5.6	24	1.4	30	1.8	20	1.2
		5-9	886	10	1.1	40	4.5	13	1.5	24	2.7	23	2.6
		10-14	664	11	1.7	53	8.0	16	2.4	14	2.1	21	3.2
		15-20	269	6	2.3	23	8.6	3	1.1	11	4.1	12	4.5
	Treatment	Surgery only	2	.	.	.	.	.	.	.	.	.	.
		Chemotherapy, no radiation	1678	13	0.8	78	4.7	13	0.8	27	1.6	19	1.1
		Radiation, no chemotherapy	1	.	.	.	.	.	.	.	.	.	.
		Chemotherapy and radiation	1696	28	1.7	137	8.2	44	2.6	49	2.9	54	3.2
		Unknown	295	5	1.7	13	4.4	2	0.7	6	2.0	7	2.4

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included

				Diabetes-pills (E.6/E.6) <sup>1</sup>		Diabetes-insulin (E.7/E.7) <sup>1</sup>		Growth hormone deficiency (E.8/E.8) <sup>1</sup>		Osteoporosis (E.10/E.10) <sup>1</sup>		Any hormonal problem <sup>2</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
		25-29	731	21	2.9	33	4.5	34	4.8	65	8.9	191	26.9
		30-34	397	9	2.3	17	4.3	6	1.6	45	11.5	104	27.3
		35+	173	11	6.5	16	9.4	6	3.6	16	9.4	54	32.3
	Years since diagnosis	5-9	423	2	0.5	16	3.8	14	3.4	24	5.8	56	13.7
		10-14	1223	9	0.7	37	3.0	61	5.1	78	6.4	218	18.2
		15-19	1185	16	1.4	29	2.5	71	6.2	79	6.7	238	20.9
		20+	841	29	3.5	32	3.8	46	5.6	60	7.2	226	27.8
	Age at diagnosis	<1	129	3	2.3	7	5.5	16	12.5	7	5.4	35	27.3
		1-4	1724	19	1.1	20	1.2	115	6.8	69	4.0	294	17.6
		5-9	886	13	1.5	20	2.3	46	5.3	57	6.5	155	18.1
		10-14	664	9	1.4	49	7.4	14	2.2	78	11.9	182	28.4
		15-20	269	12	4.7	18	6.8	1	0.4	30	11.3	72	27.9
	Treatment	Surgery only	2	.	.	.	.	.	.	.	.	.	.
		Chemotherapy, no radiation	1678	19	1.1	34	2.0	39	2.3	107	6.4	255	15.5
		Radiation, no chemotherapy	1	.	.	1	.	.	.	.	.	1	.
		Chemotherapy and radiation	1696	32	2.0	67	4.0	140	8.6	116	6.9	429	26.5
		Unknown	295	5	1.7	12	4.1	13	4.5	18	6.1	53	18.3

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included



				Overactive thyroid (E.1/E.1) <sup>1</sup>		Underactive thyroid (E.2/E.2) <sup>1</sup>		Thyroid nodules (E.3/E.3) <sup>1</sup>		Thyroid enlargement (E.4/E.4) <sup>1</sup>		Diabetes-diet (E.5/E.5) <sup>1</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		6615	66	1.0	279	4.2	54	0.8	94	1.4	96	1.5
	Age at baseline	<18	1940	10	0.5	61	3.2	4	0.2	12	0.6	17	0.9
		18-19	730	5	0.7	27	3.7	5	0.7	9	1.2	6	0.8
		20-24	1687	14	0.8	79	4.7	11	0.7	23	1.4	14	0.8
		25-29	1329	21	1.6	59	4.5	14	1.1	25	1.9	28	2.1
		30-34	649	13	2.0	35	5.4	12	1.9	15	2.3	17	2.6
		35+	280	3	1.1	18	6.5	8	2.9	10	3.6	14	5.0
	Years since diagnosis	5-9	844	4	0.5	11	1.3	3	0.4	6	0.7	8	1.0
		10-14	2223	16	0.7	79	3.6	3	0.1	19	0.9	27	1.2
		15-19	2022	22	1.1	91	4.5	14	0.7	29	1.4	19	0.9
		20+	1526	24	1.6	98	6.5	34	2.2	40	2.6	42	2.8
	Age at diagnosis	<1	133	1	0.8	16	12.1	4	3.0	3	2.3	7	5.3
		1-4	3298	26	0.8	142	4.3	26	0.8	39	1.2	25	0.8
		5-9	1691	15	0.9	59	3.5	9	0.5	26	1.5	23	1.4
		10-14	1026	16	1.6	42	4.1	10	1.0	13	1.3	24	2.4
		15-20	467	8	1.7	20	4.3	5	1.1	13	2.8	17	3.6
	Treatment	Chemotherapy, no radiation	2684	16	0.6	71	2.7	8	0.3	24	0.9	26	1.0
		Radiation, no chemotherapy	4	.	.	.	.	.	.	.	.	.	.
		Chemotherapy and radiation	3298	41	1.3	186	5.7	44	1.3	64	2.0	66	2.0
		Unknown	629	9	1.4	22	3.5	2	0.3	6	1.0	4	0.6
Males	All cases		3562	33	0.9	132	3.7	21	0.6	33	0.9	36	1.0
	Age at baseline	<18	1060	8	0.8	37	3.5	2	0.2	7	0.7	2	0.2
		18-19	398	1	0.3	16	4.0	1	0.3	3	0.8	4	1.0
		20-24	857	5	0.6	35	4.1	3	0.4	8	0.9	6	0.7
		25-29	733	13	1.8	28	3.8	8	1.1	9	1.2	14	1.9
		30-34	347	3	0.9	8	2.3	4	1.2	4	1.2	4	1.2
		35+	167	3	1.8	8	4.8	3	1.8	2	1.2	6	3.6
	Years since diagnosis	5-9	481	2	0.4	6	1.3	1	0.2	2	0.4	1	0.2
		10-14	1201	10	0.8	46	3.9	2	0.2	8	0.7	8	0.7
		15-19	1054	10	1.0	36	3.4	2	0.2	12	1.1	7	0.7
		20+	826	11	1.3	44	5.4	16	2.0	11	1.3	20	2.4
	Age at diagnosis	<1	64	1	1.6	8	12.5	1	1.6	.	.	3	4.7
		1-4	1758	13	0.7	69	3.9	10	0.6	17	1.0	11	0.6
		5-9	922	7	0.8	38	4.1	6	0.7	8	0.9	8	0.9
		10-14	525	7	1.3	11	2.1	2	0.4	4	0.8	8	1.5
		15-20	293	5	1.7	6	2.0	2	0.7	4	1.4	6	2.0
	Treatment	Chemotherapy, no radiation	1344	7	0.5	26	1.9	5	0.4	5	0.4	11	0.8
		Radiation, no chemotherapy	3	.	.	.	.	.	.	.	.	.	.
		Chemotherapy and radiation	1834	21	1.2	93	5.1	16	0.9	27	1.5	23	1.3
		Unknown	381	5	1.3	13	3.4	.	.	1	0.3	2	0.5
Females	All cases		3053	33	1.1	147	4.8	33	1.1	61	2.0	60	2.0
	Age at baseline	<18	880	2	0.2	24	2.7	2	0.2	5	0.6	15	1.7
		18-19	332	4	1.2	11	3.4	4	1.2	6	1.8	2	0.6
		20-24	830	9	1.1	44	5.3	8	1.0	15	1.8	8	1.0
		25-29	596	8	1.3	31	5.2	6	1.0	16	2.7	14	2.4
		30-34	302	10	3.3	27	9.0	8	2.7	11	3.7	13	4.3

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems

n=7 participants with no baseline information are not included

				Diabetes-pills (E.6/E.6) <sup>1</sup>		Diabetes-insulin (E.7/E.7) <sup>1</sup>		Growth hormone deficiency (E.8/E.8) <sup>1</sup>		Osteoporosis (E.10/E.10) <sup>1</sup>		Any hormonal problem <sup>2</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		6615	62	1.0	168	2.6	414	6.4	349	5.3	1121	17.4
	Age at baseline	<18	1940	5	0.3	25	1.3	150	7.8	96	5.0	291	15.2
		18-19	730	3	0.4	7	1.0	74	10.5	47	6.5	132	18.8
		20-24	1687	7	0.4	37	2.2	102	6.3	83	4.9	265	16.3
		25-29	1329	24	1.8	49	3.7	74	5.7	80	6.0	261	20.2
		30-34	649	12	1.9	29	4.5	11	1.8	33	5.1	110	17.6
		35+	280	11	4.0	21	7.6	3	1.1	10	3.6	62	22.5
	Years since diagnosis	5-9	844	2	0.2	30	3.6	38	4.5	46	5.5	121	14.6
		10-14	2223	10	0.5	51	2.3	144	6.6	132	6.0	359	16.5
		15-19	2022	17	0.9	42	2.1	133	6.8	106	5.3	330	17.0
		20+	1526	33	2.2	45	3.0	99	6.6	65	4.3	311	21.0
	Age at diagnosis	<1	133	2	1.5	7	5.3	28	21.2	11	8.3	42	31.8
		1-4	3298	25	0.8	29	0.9	279	8.6	141	4.3	533	16.6
		5-9	1691	9	0.5	26	1.5	87	5.3	99	5.9	255	15.6
		10-14	1026	13	1.3	71	6.9	16	1.6	70	6.9	197	19.7
		15-20	467	13	2.9	35	7.5	4	0.9	28	6.0	94	20.8
	Treatment	Chemotherapy, no radiation	2684	21	0.8	51	1.9	51	1.9	153	5.7	326	12.4
		Radiation, no chemotherapy	4	.	.	1	25.0	.	.	1	25.0	2	50.0
		Chemotherapy and radiation	3298	38	1.2	101	3.1	317	10.0	170	5.2	692	21.8
		Unknown	629	3	0.5	15	2.4	46	7.4	25	4.0	101	16.3
Males	All cases		3562	27	0.8	76	2.1	284	8.1	183	5.2	591	17.0
	Age at baseline	<18	1060	.	.	9	0.9	103	9.8	59	5.6	180	17.2
		18-19	398	3	0.8	6	1.5	53	13.7	29	7.3	80	20.7
		20-24	857	4	0.5	16	1.9	67	8.1	43	5.0	135	16.3
		25-29	733	8	1.1	21	2.9	52	7.2	38	5.2	126	17.6
		30-34	347	6	1.8	14	4.1	7	2.1	10	2.9	40	11.8
		35+	167	6	3.6	10	6.0	2	1.2	4	2.4	30	18.3
	Years since diagnosis	5-9	481	.	.	17	3.5	26	5.4	25	5.2	72	15.1
		10-14	1201	3	0.3	20	1.7	107	9.0	79	6.6	211	17.9
		15-19	1054	7	0.7	18	1.7	84	8.3	49	4.7	160	15.7
		20+	826	17	2.1	21	2.6	67	8.3	30	3.7	148	18.4
	Age at diagnosis	<1	64	.	.	1	1.6	16	25.4	5	7.8	20	31.7
		1-4	1758	12	0.7	13	0.7	186	10.8	83	4.7	295	17.2
		5-9	922	3	0.3	13	1.4	67	7.5	55	6.0	149	16.7
		10-14	525	8	1.5	29	5.6	12	2.3	25	4.8	78	15.0
		15-20	293	4	1.4	20	6.8	3	1.0	15	5.1	49	17.1
	Treatment	Chemotherapy, no radiation	1344	7	0.5	25	1.9	32	2.4	75	5.6	152	11.5
		Radiation, no chemotherapy	3	.	.	.	.	.	.	1	33.3	1	33.3
		Chemotherapy and radiation	1834	18	1.0	43	2.4	215	12.1	94	5.1	377	21.2
		Unknown	381	2	0.5	8	2.1	37	9.8	13	3.4	61	16.1
Females	All cases		3053	35	1.2	92	3.0	130	4.4	166	5.5	530	17.9
	Age at baseline	<18	880	5	0.6	16	1.8	47	5.4	37	4.2	111	12.8
		18-19	332	.	.	1	0.3	21	6.5	18	5.5	52	16.5
		20-24	830	3	0.4	21	2.5	35	4.4	40	4.9	130	16.4
		25-29	596	16	2.7	28	4.7	22	3.8	42	7.1	135	23.4
		30-34	302	6	2.1	15	5.0	4	1.4	23	7.7	70	24.4

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included

				Overactive thyroid (E.1/E.1) <sup>1</sup>		Underactive thyroid (E.2/E.2) <sup>1</sup>		Thyroid nodules (E.3/E.3) <sup>1</sup>		Thyroid enlargement (E.4/E.4) <sup>1</sup>		Diabetes-diet (E.5/E.5) <sup>1</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
		35+	113	.	.	10	9.0	5	4.5	8	7.2	8	7.1
	Years since diagnosis	5-9	363	2	0.6	5	1.4	2	0.6	4	1.1	7	1.9
		10-14	1022	6	0.6	33	3.2	1	0.1	11	1.1	19	1.9
		15-19	968	12	1.3	55	5.7	12	1.3	17	1.8	12	1.2
		20+	700	13	1.9	54	7.8	18	2.6	29	4.2	22	3.2
	Age at diagnosis	<1	69	.	.	8	11.8	3	4.4	3	4.4	4	5.9
		1-4	1540	13	0.8	73	4.8	16	1.1	22	1.4	14	0.9
		5-9	769	8	1.0	21	2.7	3	0.4	18	2.3	15	2.0
		10-14	501	9	1.8	31	6.2	8	1.6	9	1.8	16	3.2
		15-20	174	3	1.7	14	8.1	3	1.8	9	5.2	11	6.4
	Treatment	Chemotherapy, no radiation	1340	9	0.7	45	3.4	3	0.2	19	1.4	15	1.1
		Radiation, no chemotherapy	1	.	.	.	.	.	.	.	.	.	.
		Chemotherapy and radiation	1464	20	1.4	93	6.4	28	1.9	37	2.5	43	2.9
		Unknown	248	4	1.6	9	3.6	2	0.8	5	2.0	2	0.8

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included

				Diabetes-pills (E.6/E.6) <sup>1</sup>		Diabetes-insulin (E.7/E.7) <sup>1</sup>		Growth hormone deficiency (E.8/E.8) <sup>1</sup>		Osteoporosis (E.10/E.10) <sup>1</sup>		Any hormonal problem <sup>2</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
		35+	113	5	4.5	11	9.8	1	0.9	6	5.4	32	28.8
	Years since diagnosis	5-9	363	2	0.6	13	3.6	12	3.3	21	5.9	49	13.8
		10-14	1022	7	0.7	31	3.0	37	3.7	53	5.2	148	14.8
		15-19	968	10	1.1	24	2.5	49	5.3	57	5.9	170	18.4
		20+	700	16	2.3	24	3.5	32	4.7	35	5.1	163	24.1
	Age at diagnosis	<1	69	2	2.9	6	8.8	12	17.4	6	8.7	22	31.9
		1-4	1540	13	0.9	16	1.0	93	6.2	58	3.8	238	15.9
		5-9	769	6	0.8	13	1.7	20	2.7	44	5.8	106	14.3
		10-14	501	5	1.0	42	8.4	4	0.8	45	9.1	119	24.6
		15-20	174	9	5.4	15	8.7	1	0.6	13	7.6	45	26.9
	Treatment	Chemotherapy, no radiation	1340	14	1.1	26	1.9	19	1.4	78	5.9	174	13.2
		Radiation, no chemotherapy	1	.	.	1	.	.	.	.	.	1	.
		Chemotherapy and radiation	1464	20	1.4	58	4.0	102	7.3	76	5.2	315	22.5
		Unknown	248	1	0.4	7	2.8	9	3.7	12	4.9	40	16.5

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included

				Overactive thyroid (E.1/E.1) <sup>1</sup>		Underactive thyroid (E.2/E.2) <sup>1</sup>		Thyroid nodules (E.3/E.3) <sup>1</sup>		Thyroid enlargement (E.4/E.4) <sup>1</sup>		Diabetes-diet (E.5/E.5) <sup>1</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		927	18	2.0	112	12.2	26	2.8	21	2.3	26	2.8
	Age at baseline	<18	230	4	1.8	27	11.8	2	0.9	2	0.9	2	0.9
		18-19	89	1	1.2	13	15.1	3	3.5	3	3.5	3	3.5
		20-24	199	6	3.0	29	14.7	9	4.5	4	2.0	6	3.0
		25-29	200	3	1.5	21	10.6	7	3.5	7	3.5	7	3.5
		30-34	133	3	2.3	11	8.3	2	1.5	2	1.5	4	3.1
		35+	76	1	1.4	11	14.9	3	4.2	3	4.1	4	5.4
	Years since diagnosis	5-9	85	.	.	4	4.8	2	2.4	1	1.2	.	.
		10-14	319	6	1.9	42	13.3	6	1.9	8	2.5	2	0.6
		15-19	323	8	2.5	33	10.2	10	3.1	5	1.6	13	4.0
		20+	200	4	2.0	33	16.8	8	4.1	7	3.6	11	5.6
	Age at diagnosis	<1	93	1	1.1	15	16.3	1	1.1	.	.	3	3.3
		1-4	314	8	2.6	40	12.9	9	2.9	7	2.2	10	3.2
		5-9	171	4	2.4	22	13.1	8	4.7	6	3.5	5	2.9
		10-14	198	2	1.0	23	11.7	5	2.6	4	2.1	4	2.1
		15-20	151	3	2.0	12	8.0	3	2.0	4	2.7	4	2.7
	Treatment	Surgery only	3	.	.	.	.	.	.	.	.	.	.
		Chemotherapy, no radiation	557	6	1.1	50	9.1	10	1.8	11	2.0	8	1.4
		Chemotherapy and radiation	295	10	3.4	56	19.2	16	5.5	8	2.7	15	5.1
		Unknown	72	2	2.8	6	8.5	.	.	2	2.8	3	4.2
Males	All cases		454	6	1.3	49	10.9	9	2.0	7	1.6	11	2.4
	Age at baseline	<18	125	3	2.4	15	12.1	2	1.6	2	1.6	2	1.6
		18-19	45	.	.	10	23.3	1	2.3	1	2.3	1	2.3
		20-24	95	.	.	9	9.5	2	2.1	.	.	2	2.1
		25-29	90	2	2.3	7	7.9	2	2.2	2	2.2	2	2.2
		30-34	64	1	1.6	6	9.4	1	1.6	1	1.6	2	3.2
		35+	35	.	.	2	5.9	1	3.0	1	2.9	2	5.9
	Years since diagnosis	5-9	50	.	.	2	4.1	1	2.0	1	2.0	.	.
		10-14	159	2	1.3	20	12.7	2	1.3	3	1.9	1	0.6
		15-19	149	1	0.7	13	8.8	4	2.7	1	0.7	5	3.4
		20+	96	3	3.2	14	14.9	2	2.2	2	2.1	5	5.4
	Age at diagnosis	<1	40	.	.	7	17.9	1	2.6	.	.	3	7.7
		1-4	171	3	1.8	24	14.2	4	2.4	2	1.2	4	2.4
		5-9	79	3	3.8	8	10.3	1	1.3	2	2.5	.	.
		10-14	81	.	.	6	7.5	.	.	1	1.3	1	1.3
		15-20	83	.	.	4	4.8	3	3.7	2	2.4	3	3.6
	Treatment	Surgery only	1	.	.	.	.	.	.	.	.	.	.
		Chemotherapy, no radiation	269	2	0.7	24	9.0	1	0.4	3	1.1	4	1.5
		Chemotherapy and radiation	145	2	1.4	23	16.1	8	5.6	3	2.1	7	4.9
		Unknown	39	2	5.3	2	5.3	.	.	1	2.6	.	.
Females	All cases		473	12	2.6	63	13.5	17	3.6	14	3.0	15	3.2
	Age at baseline	<18	105	1	1.0	12	11.5	.	.	.	.	.	.
		18-19	44	1	2.3	3	7.0	2	4.7	2	4.7	2	4.7
		20-24	104	6	5.8	20	19.6	7	6.7	4	3.8	4	3.8
		25-29	110	1	0.9	14	12.7	5	4.5	5	4.5	5	4.5
		30-34	69	2	2.9	5	7.2	1	1.4	1	1.4	2	2.9

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems

n=7 participants with no baseline information are not included

				Diabetes-pills (E.6/E.6) <sup>1</sup>		Diabetes-insulin (E.7/E.7) <sup>1</sup>		Growth hormone deficiency (E.8/E.8) <sup>1</sup>		Osteoporosis (E.10/E.10) <sup>1</sup>		Any hormonal problem <sup>2</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		927	27	3.0	27	2.9	96	10.5	80	8.7	261	28.8
	Age at baseline	<18	230	3	1.3	5	2.2	31	13.7	12	5.3	60	26.5
		18-19	89	2	2.4	1	1.2	14	16.3	8	9.3	28	32.9
		20-24	199	5	2.5	8	4.1	27	13.6	13	6.5	61	30.8
		25-29	200	10	5.1	6	3.0	17	8.8	20	10.1	58	29.9
		30-34	133	.	.	1	0.8	3	2.3	16	12.0	30	22.7
		35+	76	7	9.9	6	8.1	4	5.6	11	15.1	24	34.3
	Years since diagnosis	5-9	85	.	.	.	.	4	5.0	6	7.1	14	17.7
		10-14	319	4	1.3	10	3.2	41	13.1	31	9.8	96	30.6
		15-19	323	10	3.1	8	2.5	34	10.6	18	5.6	80	25.0
		20+	200	13	6.7	9	4.6	17	8.7	25	12.8	71	37.0
	Age at diagnosis	<1	93	3	3.3	3	3.3	11	12.1	6	6.6	24	26.4
		1-4	314	9	2.9	9	2.9	45	14.5	18	5.8	95	30.8
		5-9	171	7	4.1	6	3.5	26	15.2	14	8.2	55	32.4
		10-14	198	3	1.6	4	2.1	13	6.7	29	14.9	56	29.0
		15-20	151	5	3.5	5	3.4	1	0.7	13	8.7	31	21.7
	Treatment	Surgery only	3	.	.	.	.	.	.	.	.	.	.
		Chemotherapy, no radiation	557	8	1.5	12	2.2	30	5.4	32	5.8	117	21.4
		Chemotherapy and radiation	295	16	5.6	13	4.5	61	21.3	41	14.1	129	45.3
		Unknown	72	3	4.2	2	2.8	5	7.0	7	9.7	15	21.4
Males	All cases		454	13	2.9	12	2.7	49	10.9	31	6.9	114	25.6
	Age at baseline	<18	125	2	1.6	4	3.2	20	16.0	10	8.0	39	31.5
		18-19	45	.	.	.	.	7	16.3	5	11.4	17	39.5
		20-24	95	1	1.1	3	3.2	11	11.6	6	6.3	24	25.3
		25-29	90	6	6.8	2	2.2	8	9.1	5	5.6	18	20.7
		30-34	64	.	.	1	1.6	3	4.7	2	3.1	9	14.1
		35+	35	4	12.5	2	5.9	.	.	3	9.1	7	21.9
	Years since diagnosis	5-9	50	.	.	.	.	3	6.1	4	8.0	11	22.9
		10-14	159	2	1.3	5	3.2	23	14.6	14	8.8	46	29.3
		15-19	149	4	2.7	3	2.0	15	10.1	5	3.4	28	18.9
		20+	96	7	7.6	4	4.3	8	8.5	8	8.6	29	31.5
	Age at diagnosis	<1	40	2	5.1	2	5.1	7	17.9	5	13.2	12	30.8
		1-4	171	4	2.4	5	2.9	25	14.6	10	5.8	55	32.4
		5-9	79	2	2.5	1	1.3	10	12.7	5	6.3	21	26.9
		10-14	81	2	2.6	1	1.3	6	7.6	9	11.4	14	17.7
		15-20	83	3	3.8	3	3.6	1	1.3	2	2.4	12	15.2
	Treatment	Surgery only	1	.	.	.	.	.	.	.	.	.	.
		Chemotherapy, no radiation	269	4	1.5	7	2.6	14	5.2	10	3.7	52	19.5
		Chemotherapy and radiation	145	8	5.7	5	3.5	32	22.7	18	12.6	56	40.0
		Unknown	39	1	2.6	.	.	3	7.7	3	7.7	6	15.8
Females	All cases		473	14	3.0	15	3.2	47	10.2	49	10.5	147	32.0
	Age at baseline	<18	105	1	1.0	1	1.0	11	10.8	2	1.9	21	20.6
		18-19	44	2	4.7	1	2.3	7	16.3	3	7.1	11	26.2
		20-24	104	4	3.8	5	4.9	16	15.4	7	6.7	37	35.9
		25-29	110	4	3.7	4	3.7	9	8.5	15	13.6	40	37.4
		30-34	69	.	.	.	.	.	.	14	20.3	21	30.9

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems

n=7 participants with no baseline information are not included

				Overactive thyroid (E.1/E.1) <sup>1</sup>		Underactive thyroid (E.2/E.2) <sup>1</sup>		Thyroid nodules (E.3/E.3) <sup>1</sup>		Thyroid enlargement (E.4/E.4) <sup>1</sup>		Diabetes-diet (E.5/E.5) <sup>1</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
		35+	41	1	2.5	9	22.5	2	5.1	2	5.0	2	5.0
	Years since diagnosis	5-9	35	.	.	2	5.9	1	2.9	.	.	.	.
		10-14	160	4	2.5	22	14.0	4	2.5	5	3.1	1	0.6
		15-19	174	7	4.0	20	11.5	6	3.4	4	2.3	8	4.6
		20+	104	1	1.0	19	18.4	6	5.9	5	4.9	6	5.8
	Age at diagnosis	<1	53	1	1.9	8	15.1	.	.	.	.	.	.
		1-4	143	5	3.5	16	11.3	5	3.5	5	3.5	6	4.2
		5-9	92	1	1.1	14	15.6	7	7.6	4	4.3	5	5.4
		10-14	117	2	1.7	17	14.7	5	4.3	3	2.6	3	2.6
		15-20	68	3	4.5	8	11.9	.	.	2	3.0	1	1.5
	Treatment	Surgery only	2	.	.	.	.	.	.	.	.	.	.
		Chemotherapy, no radiation	288	4	1.4	26	9.1	9	3.1	8	2.8	4	1.4
		Chemotherapy and radiation	150	8	5.4	33	22.3	8	5.4	5	3.4	8	5.4
		Unknown	33	.	.	4	12.1	.	.	1	3.0	3	9.1

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'

<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included

				Diabetes- pills (E.6/E.6) <sup>1</sup>		Diabetes- insulin (E.7/E.7) <sup>1</sup>		Growth hormone deficiency (E.8/E.8) <sup>1</sup>		Osteoporosis (E.10/E.10) <sup>1</sup>		Any hormonal problem <sup>2</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
		35+	41	3	7.7	4	10.0	4	10.3	8	20.0	17	44.7
	Years since diagnosis	5-9	35	.	.	.	.	1	3.2	2	5.9	3	9.7
		10-14	160	2	1.3	5	3.2	18	11.5	17	10.8	50	31.8
		15-19	174	6	3.5	5	2.9	19	10.9	13	7.5	52	30.2
		20+	104	6	5.9	5	4.9	9	8.9	17	16.5	42	42.0
	Age at diagnosis	<1	53	1	1.9	1	1.9	4	7.7	1	1.9	12	23.1
		1-4	143	5	3.5	4	2.8	20	14.3	8	5.7	40	29.0
		5-9	92	5	5.4	5	5.5	16	17.4	9	9.8	34	37.0
		10-14	117	1	0.9	3	2.6	7	6.0	20	17.2	42	36.8
		15-20	68	2	3.2	2	3.0	.	.	11	16.4	19	29.7
	Treatment	Surgery only	2	.	.	.	.	.	.	.	.	.	.
		Chemotherapy, no radiation	288	4	1.4	5	1.8	16	5.6	22	7.7	65	23.1
		Chemotherapy and radiation	150	8	5.5	8	5.4	29	20.0	23	15.5	73	50.3
		Unknown	33	2	6.1	2	6.1	2	6.3	4	12.1	9	28.1

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'

<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included



				Overactive thyroid (E.1/E.1) <sup>1</sup>		Underactive thyroid (E.2/E.2) <sup>1</sup>		Thyroid nodules (E.3/E.3) <sup>1</sup>		Thyroid enlargement (E.4/E.4) <sup>1</sup>		Diabetes-diet (E.5/E.5) <sup>1</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		4490	113	2.6	850	19.2	76	1.7	82	1.8	41	0.9
	Age at baseline	<18	953	16	1.7	193	20.4	8	0.8	6	0.6	7	0.7
		18-19	377	8	2.1	74	19.8	7	1.9	6	1.6	1	0.3
		20-24	1179	29	2.5	241	20.7	15	1.3	22	1.9	6	0.5
		25-29	1084	31	2.9	200	18.8	22	2.1	24	2.2	10	0.9
		30-34	623	20	3.3	105	17.0	16	2.6	14	2.3	8	1.3
		35+	274	9	3.3	37	13.8	8	3.0	10	3.7	9	3.3
	Years since diagnosis	5-9	463	9	2.0	92	20.0	1	0.2	1	0.2	3	0.7
		10-14	1540	33	2.2	294	19.2	18	1.2	20	1.3	13	0.8
		15-19	1415	34	2.4	267	19.1	27	1.9	30	2.1	6	0.4
		20+	1072	37	3.5	197	18.7	30	2.9	31	2.9	19	1.8
	Age at diagnosis	<1	218	2	0.9	41	19.1	.	.	.	.	3	1.4
		1-4	1322	30	2.3	254	19.4	24	1.8	24	1.8	6	0.5
		5-9	1405	35	2.5	311	22.5	30	2.2	27	1.9	11	0.8
		10-14	1067	37	3.5	189	17.9	13	1.2	22	2.1	14	1.3
		15-20	478	9	1.9	55	11.6	9	1.9	9	1.9	7	1.5
	Treatment	Surgery only	1272	20	1.6	59	4.7	8	0.6	15	1.2	10	0.8
		Chemotherapy, no radiation	355	10	2.9	49	13.9	3	0.9	6	1.7	7	2.0
		Radiation, no chemotherapy	1171	21	1.8	214	18.5	22	1.9	22	1.9	8	0.7
		Chemotherapy and radiation	1249	52	4.3	467	38.1	39	3.2	34	2.8	12	1.0
		Unknown	443	10	2.3	61	13.9	4	0.9	5	1.1	4	0.9
Males	All cases		2452	65	2.7	479	19.7	29	1.2	29	1.2	17	0.7
	Age at baseline	<18	529	13	2.5	117	22.2	4	0.8	3	0.6	5	1.0
		18-19	191	4	2.1	37	19.5	4	2.1	3	1.6	1	0.5
		20-24	633	16	2.6	143	22.8	5	0.8	8	1.3	1	0.2
		25-29	618	21	3.4	109	17.9	5	0.8	8	1.3	2	0.3
		30-34	332	6	1.8	57	17.2	4	1.2	3	0.9	4	1.2
		35+	149	5	3.4	16	10.9	7	4.8	4	2.7	4	2.7
	Years since diagnosis	5-9	263	4	1.5	57	21.8	.	.	1	0.4	2	0.8
		10-14	832	24	2.9	175	21.1	7	0.8	5	0.6	7	0.8
		15-19	772	17	2.2	144	18.9	12	1.6	13	1.7	1	0.1
		20+	585	20	3.5	103	17.8	10	1.7	10	1.7	7	1.2
	Age at diagnosis	<1	128	1	0.8	28	22.2	.	.	.	.	1	0.8
		1-4	698	21	3.0	140	20.2	11	1.6	12	1.7	2	0.3
		5-9	786	21	2.7	180	23.2	8	1.0	10	1.3	7	0.9
		10-14	570	18	3.2	106	18.7	3	0.5	3	0.5	3	0.5
		15-20	270	4	1.5	25	9.3	7	2.6	4	1.5	4	1.5
	Treatment	Surgery only	649	9	1.4	24	3.7	1	0.2	2	0.3	4	0.6
		Chemotherapy, no radiation	191	9	4.8	30	15.9	1	0.5	2	1.1	3	1.6
		Radiation, no chemotherapy	616	11	1.8	111	18.2	10	1.6	8	1.3	1	0.2
		Chemotherapy and radiation	742	29	4.0	282	38.5	15	2.1	13	1.8	7	1.0
		Unknown	254	7	2.8	32	12.7	2	0.8	4	1.6	2	0.8
Females	All cases		2038	48	2.4	371	18.5	47	2.3	53	2.6	24	1.2
	Age at baseline	<18	424	3	0.7	76	18.2	4	1.0	3	0.7	2	0.5
		18-19	186	4	2.2	37	20.1	3	1.7	3	1.6	.	.
		20-24	546	13	2.4	98	18.2	10	1.8	14	2.6	5	0.9

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems

n=7 participants with no baseline information are not included

				Diabetes-pills (E.6/E.6) <sup>1</sup>		Diabetes-insulin (E.7/E.7) <sup>1</sup>		Growth hormone deficiency (E.8/E.8) <sup>1</sup>		Osteoporosis (E.10/E.10) <sup>1</sup>		Any hormonal problem <sup>2</sup>		
				All cases	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		4490	52	1.2	35	0.8	976	22.2	275	6.2	1546	35.3	
	Age at baseline	<18	953	5	0.5	8	0.8	306	32.4	45	4.8	388	41.5	
		18-19	377	2	0.5	2	0.5	106	29.2	27	7.2	141	39.0	
		20-24	1179	11	0.9	8	0.7	280	24.2	81	7.0	416	36.0	
		25-29	1084	19	1.8	6	0.6	206	19.4	75	7.0	363	34.3	
		30-34	623	8	1.3	5	0.8	67	11.1	35	5.7	170	28.3	
		35+	274	7	2.6	6	2.2	11	4.1	12	4.4	68	25.6	
	Years since diagnosis	5-9	463	3	0.7	4	0.9	127	28.0	25	5.4	174	38.7	
		10-14	1540	10	0.7	8	0.5	346	23.0	97	6.4	538	35.7	
		15-19	1415	13	0.9	12	0.9	307	22.1	77	5.5	476	34.4	
		20+	1072	26	2.5	11	1.0	196	18.7	76	7.2	358	34.5	
	Age at diagnosis	<1	218	1	0.5	1	0.5	54	25.1	13	6.0	74	34.7	
		1-4	1322	14	1.1	7	0.5	387	29.8	77	5.9	510	39.6	
		5-9	1405	16	1.2	14	1.0	378	27.5	99	7.1	543	39.7	
		10-14	1067	12	1.1	6	0.6	137	13.0	66	6.3	326	31.0	
		15-20	478	9	2.0	7	1.5	20	4.4	20	4.2	93	20.4	
	Treatment	Surgery only	1272	7	0.6	7	0.6	33	2.6	32	2.5	138	11.1	
		Chemotherapy, no radiation	355	5	1.4	1	0.3	45	12.9	12	3.4	90	25.9	
		Radiation, no chemotherapy	1171	14	1.2	8	0.7	273	24.1	70	6.0	433	38.4	
		Chemotherapy and radiation	1249	22	1.8	15	1.2	550	45.0	141	11.5	758	62.2	
		Unknown	443	4	0.9	4	0.9	75	17.1	20	4.5	127	29.0	
Males	All cases		2452	18	0.7	10	0.4	583	24.3	133	5.5	847	35.5	
	Age at baseline	<18	529	3	0.6	2	0.4	178	33.8	21	4.0	228	43.7	
		18-19	191	.	.	1	0.5	59	32.2	15	7.9	74	40.4	
		20-24	633	2	0.3	2	0.3	176	28.3	42	6.7	239	38.5	
		25-29	618	8	1.3	2	0.3	121	19.9	37	6.0	191	31.7	
		30-34	332	4	1.2	2	0.6	41	12.8	14	4.3	83	26.3	
		35+	149	1	0.7	1	0.7	8	5.5	4	2.7	32	22.2	
	Years since diagnosis	5-9	263	2	0.8	1	0.4	79	31.0	15	5.7	108	42.5	
		10-14	832	4	0.5	3	0.4	203	24.8	48	5.8	303	37.2	
		15-19	772	3	0.4	2	0.3	187	24.7	38	5.0	262	34.8	
		20+	585	9	1.6	4	0.7	114	19.9	32	5.5	174	30.7	
	Age at diagnosis	<1	128	1	0.8	.	.	30	23.6	6	4.8	42	33.6	
		1-4	698	4	0.6	1	0.1	233	33.9	30	4.3	281	41.0	
		5-9	786	8	1.0	6	0.8	215	27.8	56	7.2	306	40.0	
		10-14	570	1	0.2	1	0.2	95	16.8	32	5.7	173	30.8	
		15-20	270	4	1.6	2	0.7	10	3.9	9	3.4	45	17.9	
	Treatment	Surgery only	649	3	0.5	3	0.5	21	3.3	17	2.6	63	10.0	
		Chemotherapy, no radiation	191	2	1.1	.	.	22	11.6	4	2.1	48	25.7	
		Radiation, no chemotherapy	616	4	0.7	2	0.3	149	24.9	30	4.9	223	37.7	
		Chemotherapy and radiation	742	6	0.8	4	0.5	342	46.9	76	10.4	442	61.0	
		Unknown	254	3	1.2	1	0.4	49	19.5	6	2.4	71	28.3	
Females	All cases		2038	34	1.7	25	1.2	393	19.7	142	7.0	699	35.1	
	Age at baseline	<18	424	2	0.5	6	1.4	128	30.7	24	5.7	160	38.7	
		18-19	186	2	1.1	1	0.5	47	26.1	12	6.5	67	37.4	
		20-24	546	9	1.7	6	1.1	104	19.5	39	7.2	177	33.1	

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included

				Overactive thyroid (E.1/E.1) <sup>1</sup>		Underactive thyroid (E.2/E.2) <sup>1</sup>		Thyroid nodules (E.3/E.3) <sup>1</sup>		Thyroid enlargement (E.4/E.4) <sup>1</sup>		Diabetes-diet (E.5/E.5) <sup>1</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
		25-29	466	10	2.2	91	20.0	17	3.7	16	3.5	8	1.7
		30-34	291	14	4.9	48	16.7	12	4.2	11	3.8	4	1.4
		35+	125	4	3.3	21	17.2	1	0.8	6	4.9	5	4.1
	Years since diagnosis	5-9	200	5	2.5	35	17.7	1	0.5	.	.	1	0.5
		10-14	708	9	1.3	119	17.1	11	1.6	15	2.1	6	0.9
		15-19	643	17	2.7	123	19.3	15	2.4	17	2.7	5	0.8
		20+	487	17	3.6	94	19.8	20	4.2	21	4.4	12	2.5
	Age at diagnosis	<1	90	1	1.1	13	14.6	.	.	.	.	2	2.2
		1-4	624	9	1.5	114	18.6	13	2.1	12	2.0	4	0.6
		5-9	619	14	2.3	131	21.6	22	3.6	17	2.8	4	0.7
		10-14	497	19	3.9	83	16.9	10	2.0	19	3.9	11	2.2
		15-20	208	5	2.4	30	14.6	2	1.0	5	2.4	3	1.5
	Treatment	Surgery only	623	11	1.8	35	5.7	7	1.1	13	2.1	6	1.0
		Chemotherapy, no radiation	164	1	0.6	19	11.7	2	1.2	4	2.5	4	2.5
		Radiation, no chemotherapy	555	10	1.8	103	18.9	12	2.2	14	2.6	7	1.3
		Chemotherapy and radiation	507	23	4.7	185	37.4	24	4.9	21	4.2	5	1.0
		Unknown	189	3	1.6	29	15.5	2	1.1	1	0.5	2	1.1

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included

				Diabetes-pills (E.6/E.6) <sup>1</sup>		Diabetes-insulin (E.7/E.7) <sup>1</sup>		Growth hormone deficiency (E.8/E.8) <sup>1</sup>		Osteoporosis (E.10/E.10) <sup>1</sup>		Any hormonal problem <sup>2</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
		25-29	466	11	2.4	4	0.9	85	18.8	38	8.3	172	37.7
		30-34	291	4	1.4	3	1.0	26	9.1	21	7.3	87	30.5
		35+	125	6	4.9	5	4.0	3	2.4	8	6.5	36	29.5
	Years since diagnosis	5-9	200	1	0.5	3	1.5	48	24.2	10	5.0	66	33.7
		10-14	708	6	0.9	5	0.7	143	20.8	49	7.0	235	34.0
		15-19	643	10	1.6	10	1.6	120	19.0	39	6.1	214	33.9
		20+	487	17	3.6	7	1.5	82	17.3	44	9.1	184	39.1
	Age at diagnosis	<1	90	.	.	1	1.1	24	27.3	7	7.9	32	36.4
		1-4	624	10	1.6	6	1.0	154	25.2	47	7.6	229	37.9
		5-9	619	8	1.3	8	1.3	163	27.1	43	7.0	237	39.3
		10-14	497	11	2.2	5	1.0	42	8.6	34	6.9	153	31.3
		15-20	208	5	2.4	5	2.4	10	4.9	11	5.3	48	23.4
	Treatment	Surgery only	623	4	0.6	4	0.6	12	1.9	15	2.4	75	12.3
		Chemotherapy, no radiation	164	3	1.9	1	0.6	23	14.4	8	4.9	42	26.3
		Radiation, no chemotherapy	555	10	1.8	6	1.1	124	23.1	40	7.3	210	39.1
		Chemotherapy and radiation	507	16	3.2	11	2.2	208	42.3	65	13.0	316	64.0
		Unknown	189	1	0.5	3	1.6	26	13.9	14	7.4	56	29.9

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included

				Overactive thyroid (E.1/E.1) <sup>1</sup>		Underactive thyroid (E.2/E.2) <sup>1</sup>		Thyroid nodules (E.3/E.3) <sup>1</sup>		Thyroid enlargement (E.4/E.4) <sup>1</sup>		Diabetes-diet (E.5/E.5) <sup>1</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		2688	56	2.1	333	12.5	23	0.9	34	1.3	25	0.9
	Age at baseline	<18	528	6	1.1	83	15.8	1	0.2	2	0.4	5	1.0
		18-19	215	4	1.9	27	12.7	3	1.4	1	0.5	.	.
		20-24	713	10	1.4	97	13.7	5	0.7	11	1.6	3	0.4
		25-29	664	20	3.1	72	11.0	5	0.8	7	1.1	8	1.2
		30-34	386	9	2.3	38	9.9	4	1.0	7	1.8	4	1.0
		35+	182	7	3.9	16	9.0	5	2.8	6	3.3	5	2.8
	Years since diagnosis	5-9	237	6	2.5	38	16.1	.	.	.	.	1	0.4
		10-14	906	9	1.0	107	11.9	4	0.4	4	0.4	9	1.0
		15-19	831	20	2.4	98	11.9	7	0.9	13	1.6	4	0.5
		20+	714	21	3.0	90	12.8	12	1.7	17	2.4	11	1.6
	Age at diagnosis	<1	150	2	1.4	34	23.1	.	.	.	.	3	2.0
		1-4	801	12	1.5	106	13.4	7	0.9	11	1.4	5	0.6
		5-9	793	17	2.2	100	12.7	9	1.1	10	1.3	3	0.4
		10-14	641	19	3.0	70	11.0	2	0.3	7	1.1	9	1.4
		15-20	303	6	2.0	23	7.7	5	1.7	6	2.0	5	1.7
	Treatment	Surgery only	1047	18	1.7	42	4.0	7	0.7	10	1.0	9	0.9
		Chemotherapy, no radiation	255	7	2.8	38	15.0	1	0.4	4	1.6	6	2.4
		Radiation, no chemotherapy	730	16	2.2	111	15.4	6	0.8	7	1.0	5	0.7
		Chemotherapy and radiation	371	9	2.5	109	30.0	6	1.7	10	2.7	3	0.8
		Unknown	285	6	2.1	33	11.7	3	1.1	3	1.1	2	0.7
Males	All cases		1405	30	2.2	173	12.4	8	0.6	13	0.9	7	0.5
	Age at baseline	<18	279	5	1.8	50	17.9	.	.	2	0.7	3	1.1
		18-19	109	2	1.8	13	12.0	1	0.9	.	.	.	.
		20-24	354	4	1.1	51	14.5	1	0.3	4	1.1	.	.
		25-29	371	12	3.3	37	10.1	1	0.3	3	0.8	1	0.3
		30-34	195	3	1.6	18	9.3	1	0.5	2	1.0	2	1.0
		35+	97	4	4.2	4	4.2	4	4.2	2	2.1	1	1.0
	Years since diagnosis	5-9	125	2	1.6	24	19.2	.	.	.	.	.	.
		10-14	479	7	1.5	62	12.9	1	0.2	2	0.4	5	1.0
		15-19	422	9	2.2	48	11.5	4	1.0	7	1.7	1	0.2
		20+	379	12	3.2	39	10.4	3	0.8	4	1.1	1	0.3
	Age at diagnosis	<1	86	1	1.2	23	27.4	.	.	.	.	1	1.2
		1-4	403	6	1.5	53	13.2	1	0.2	5	1.2	1	0.2
		5-9	421	11	2.6	54	12.9	2	0.5	4	1.0	1	0.2
		10-14	328	10	3.0	35	10.7	1	0.3	2	0.6	1	0.3
		15-20	167	2	1.2	8	4.8	4	2.4	2	1.2	3	1.8
	Treatment	Surgery only	524	7	1.3	16	3.1	1	0.2	1	0.2	3	0.6
		Chemotherapy, no radiation	142	6	4.3	25	17.7	.	.	2	1.4	2	1.4
		Radiation, no chemotherapy	370	8	2.2	57	15.5	4	1.1	5	1.4	.	.
		Chemotherapy and radiation	211	4	1.9	61	29.5	1	0.5	3	1.5	1	0.5
		Unknown	158	5	3.2	14	8.9	2	1.3	2	1.3	1	0.6
Females	All cases		1283	26	2.1	160	12.6	15	1.2	21	1.7	18	1.4
	Age at baseline	<18	249	1	0.4	33	13.5	1	0.4	.	.	2	0.8
		18-19	106	2	1.9	14	13.3	2	1.9	1	1.0	.	.
		20-24	359	6	1.7	46	12.9	4	1.1	7	2.0	3	0.8

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems

n=7 participants with no baseline information are not included

				Diabetes-pills (E.6/E.6) <sup>1</sup>		Diabetes-insulin (E.7/E.7) <sup>1</sup>		Growth hormone deficiency (E.8/E.8) <sup>1</sup>		Osteoporosis (E.10/E.10) <sup>1</sup>		Any hormonal problem <sup>2</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		2688	29	1.1	25	0.9	382	14.5	133	5.0	678	25.9
	Age at baseline	<18	528	3	0.6	5	1.0	131	25.0	21	4.0	172	33.0
		18-19	215	2	1.0	2	0.9	38	18.4	14	6.5	59	28.8
		20-24	713	5	0.7	5	0.7	109	15.5	35	5.0	180	25.9
		25-29	664	11	1.7	6	0.9	77	11.9	44	6.7	163	25.2
		30-34	386	3	0.8	4	1.0	21	5.6	11	2.9	68	18.3
		35+	182	5	2.8	3	1.7	6	3.4	8	4.4	36	20.6
	Years since diagnosis	5-9	237	1	0.4	3	1.3	50	21.6	9	3.8	72	31.2
		10-14	906	6	0.7	6	0.7	131	14.7	49	5.4	223	25.2
		15-19	831	5	0.6	7	0.8	112	13.7	34	4.1	198	24.3
		20+	714	17	2.4	9	1.3	89	12.8	41	5.8	185	27.0
	Age at diagnosis	<1	150	1	0.7	1	0.7	42	28.6	10	6.8	58	39.7
		1-4	801	8	1.0	4	0.5	162	20.6	41	5.2	234	29.9
		5-9	793	9	1.1	10	1.3	123	15.8	39	4.9	200	25.9
		10-14	641	6	0.9	6	0.9	46	7.3	31	4.9	138	22.0
		15-20	303	5	1.7	4	1.3	9	3.1	12	4.0	48	16.7
	Treatment	Surgery only	1047	3	0.3	4	0.4	26	2.5	28	2.7	107	10.5
		Chemotherapy, no radiation	255	4	1.6	1	0.4	35	13.9	10	4.0	70	28.0
		Radiation, no chemotherapy	730	10	1.4	7	1.0	160	22.6	47	6.5	246	35.0
		Chemotherapy and radiation	371	10	2.7	9	2.5	125	34.4	38	10.4	184	51.4
		Unknown	285	2	0.7	4	1.4	36	12.8	10	3.5	71	25.3
Males	All cases		1405	8	0.6	7	0.5	216	15.7	56	4.0	343	25.1
	Age at baseline	<18	279	1	0.4	1	0.4	74	26.6	6	2.2	97	35.0
		18-19	109	.	.	1	0.9	24	23.5	10	9.2	34	33.3
		20-24	354	.	.	1	0.3	62	17.9	14	4.0	90	26.0
		25-29	371	4	1.1	2	0.5	40	11.0	18	4.9	78	21.5
		30-34	195	2	1.1	1	0.5	12	6.4	5	2.6	31	16.8
		35+	97	1	1.1	1	1.1	4	4.2	3	3.1	13	14.0
	Years since diagnosis	5-9	125	.	.	1	0.8	29	24.0	5	4.0	43	35.5
		10-14	479	2	0.4	2	0.4	78	16.6	22	4.6	123	26.3
		15-19	422	1	0.2	1	0.2	63	15.3	15	3.6	101	24.6
		20+	379	5	1.3	3	0.8	46	12.4	14	3.7	76	20.9
	Age at diagnosis	<1	86	1	1.2	.	.	23	27.1	5	6.0	33	39.3
		1-4	403	1	0.3	.	.	95	24.1	10	2.5	117	29.6
		5-9	421	3	0.7	4	1.0	64	15.5	21	5.0	104	25.5
		10-14	328	1	0.3	1	0.3	31	9.5	14	4.3	67	20.8
		15-20	167	2	1.3	2	1.2	3	1.9	6	3.6	22	14.2
	Treatment	Surgery only	524	1	0.2	2	0.4	16	3.1	14	2.7	47	9.2
		Chemotherapy, no radiation	142	1	0.7	.	.	19	13.4	3	2.1	39	27.7
		Radiation, no chemotherapy	370	3	0.8	2	0.5	87	24.2	16	4.3	122	34.3
		Chemotherapy and radiation	211	1	0.5	2	1.0	69	33.7	18	8.7	96	47.5
		Unknown	158	2	1.3	1	0.6	25	16.1	5	3.2	39	25.2
Females	All cases		1283	21	1.7	18	1.4	166	13.2	77	6.1	335	26.8
	Age at baseline	<18	249	2	0.8	4	1.6	57	23.2	15	6.1	75	30.7
		18-19	106	2	1.9	1	0.9	14	13.5	4	3.8	25	24.3
		20-24	359	5	1.4	4	1.1	47	13.3	21	5.9	90	25.7

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems

n=7 participants with no baseline information are not included

				Overactive thyroid (E.1/E.1) <sup>1</sup>		Underactive thyroid (E.2/E.2) <sup>1</sup>		Thyroid nodules (E.3/E.3) <sup>1</sup>		Thyroid enlargement (E.4/E.4) <sup>1</sup>		Diabetes-diet (E.5/E.5) <sup>1</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
		25-29	293	8	2.8	35	12.2	4	1.4	4	1.4	7	2.4
		30-34	191	6	3.2	20	10.5	3	1.6	5	2.6	2	1.1
		35+	85	3	3.6	12	14.6	1	1.2	4	4.8	4	4.8
	Years since diagnosis	5-9	112	4	3.6	14	12.6	.	.	.	.	1	0.9
		10-14	427	2	0.5	45	10.7	3	0.7	2	0.5	4	0.9
		15-19	409	11	2.7	50	12.3	3	0.7	6	1.5	3	0.7
		20+	335	9	2.7	51	15.6	9	2.8	13	4.0	10	3.0
	Age at diagnosis	<1	64	1	1.6	11	17.5	.	.	.	.	2	3.1
		1-4	398	6	1.5	53	13.5	6	1.5	6	1.5	4	1.0
		5-9	372	6	1.6	46	12.5	7	1.9	6	1.6	2	0.5
		10-14	313	9	2.9	35	11.4	1	0.3	5	1.6	8	2.6
		15-20	136	4	3.0	15	11.2	1	0.7	4	3.0	2	1.5
	Treatment	Surgery only	523	11	2.1	26	5.0	6	1.2	9	1.7	6	1.2
		Chemotherapy, no radiation	113	1	0.9	13	11.6	1	0.9	2	1.8	4	3.6
		Radiation, no chemotherapy	360	8	2.3	54	15.3	2	0.6	2	0.6	5	1.4
		Chemotherapy and radiation	160	5	3.2	48	30.8	5	3.2	7	4.4	2	1.3
		Unknown	127	1	0.8	19	15.2	1	0.8	1	0.8	1	0.8

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included

				Diabetes-pills (E.6/E.6) <sup>1</sup>		Diabetes-insulin (E.7/E.7) <sup>1</sup>		Growth hormone deficiency (E.8/E.8) <sup>1</sup>		Osteoporosis (E.10/E.10) <sup>1</sup>		Any hormonal problem <sup>2</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
		25-29	293	7	2.4	4	1.4	37	13.0	26	9.0	85	29.8
		30-34	191	1	0.5	3	1.6	9	4.8	6	3.2	37	19.8
		35+	85	4	4.8	2	2.4	2	2.4	5	6.0	23	28.0
	Years since diagnosis	5-9	112	1	0.9	2	1.8	21	18.9	4	3.6	29	26.4
		10-14	427	4	1.0	4	0.9	53	12.6	27	6.4	100	24.0
		15-19	409	4	1.0	6	1.5	49	12.1	19	4.7	97	24.1
		20+	335	12	3.6	6	1.8	43	13.2	27	8.1	109	33.9
	Age at diagnosis	<1	64	.	.	1	1.6	19	30.6	5	7.9	25	40.3
		1-4	398	7	1.8	4	1.0	67	17.1	31	7.9	117	30.2
		5-9	372	6	1.6	6	1.6	59	16.2	18	4.9	96	26.4
		10-14	313	5	1.6	5	1.6	15	4.9	17	5.5	71	23.2
		15-20	136	3	2.2	2	1.5	6	4.5	6	4.4	26	19.5
	Treatment	Surgery only	523	2	0.4	2	0.4	10	1.9	14	2.7	60	11.7
		Chemotherapy, no radiation	113	3	2.7	1	0.9	16	14.7	7	6.3	31	28.4
		Radiation, no chemotherapy	360	7	2.0	5	1.4	73	20.9	31	8.8	124	35.7
		Chemotherapy and radiation	160	9	5.6	7	4.4	56	35.4	20	12.6	88	56.4
		Unknown	127	.	.	3	2.4	11	8.7	5	4.0	32	25.4

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included



				Overactive thyroid (E.1/E.1) <sup>1</sup>		Underactive thyroid (E.2/E.2) <sup>1</sup>		Thyroid nodules (E.3/E.3) <sup>1</sup>		Thyroid enlargement (E.4/E.4) <sup>1</sup>		Diabetes-diet (E.5/E.5) <sup>1</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		1040	44	4.3	404	39.6	40	3.9	29	2.8	9	0.9
	Age at baseline	<18	246	6	2.5	89	36.5	7	2.9	2	0.8	1	0.4
		18-19	83	3	3.7	33	40.2	1	1.2	2	2.4	1	1.2
		20-24	291	15	5.3	115	40.4	9	3.1	5	1.7	1	0.3
		25-29	252	9	3.7	102	41.6	12	4.9	13	5.2	1	0.4
		30-34	131	9	7.1	54	41.9	10	7.8	5	3.9	3	2.3
		35+	37	2	5.6	11	30.6	1	2.9	2	5.7	2	5.6
	Years since diagnosis	5-9	124	1	0.8	41	33.6	1	0.8	1	0.8	.	.
		10-14	355	18	5.2	140	39.8	11	3.2	7	2.0	2	0.6
		15-19	344	11	3.3	140	41.8	15	4.5	13	3.8	2	0.6
		20+	217	14	6.8	83	39.2	13	6.2	8	3.8	5	2.3
	Age at diagnosis	<1	28	.	.	4	14.3	.	.	.	.	.	.
		1-4	298	13	4.5	118	40.1	13	4.4	5	1.7	1	0.3
		5-9	422	15	3.7	182	44.3	18	4.4	14	3.4	6	1.4
		10-14	230	14	6.2	86	38.1	7	3.1	9	3.9	2	0.9
		15-20	62	2	3.2	14	22.6	2	3.3	1	1.6	.	.
	Treatment	Surgery only	8	.	.	2	25.0	.	.	.	.	.	.
		Chemotherapy, no radiation	53	2	3.9	6	11.3	1	1.9	.	.	.	.
		Radiation, no chemotherapy	208	3	1.5	62	30.8	13	6.5	9	4.5	.	.
		Chemotherapy and radiation	692	36	5.3	317	46.5	25	3.7	18	2.6	8	1.2
		Unknown	79	3	3.8	17	22.1	1	1.3	2	2.6	1	1.3
Males	All cases		632	28	4.5	248	39.9	16	2.6	11	1.8	5	0.8
	Age at baseline	<18	147	5	3.5	55	37.7	4	2.7	1	0.7	1	0.7
		18-19	47	1	2.1	19	40.4	1	2.1	1	2.1	1	2.2
		20-24	185	11	6.0	77	42.3	4	2.2	2	1.1	.	.
		25-29	157	7	4.6	58	38.2	3	2.0	5	3.2	1	0.6
		30-34	73	3	4.2	32	43.8	3	4.2	1	1.4	1	1.4
		35+	23	1	4.5	7	31.8	1	4.8	1	4.5	1	4.3
	Years since diagnosis	5-9	76	.	.	23	30.7	.	.	1	1.3	.	.
		10-14	208	12	5.9	91	44.0	5	2.4	1	0.5	2	1.0
		15-19	217	8	3.8	79	37.4	5	2.4	5	2.3	.	.
		20+	131	8	6.3	55	42.6	6	4.7	4	3.1	3	2.3
	Age at diagnosis	<1	16	.	.	3	18.8	.	.	.	.	.	.
		1-4	180	12	6.8	70	39.1	8	4.5	4	2.2	1	0.6
		5-9	267	9	3.5	117	44.8	6	2.3	5	1.9	4	1.5
		10-14	132	6	4.7	51	39.5	1	0.8	1	0.8	.	.
		15-20	37	1	2.7	7	18.9	1	2.8	1	2.7	.	.
	Treatment	Surgery only	5	.	.	2	40.0	.	.	.	.	.	.
		Chemotherapy, no radiation	27	2	7.7	3	11.1	1	3.7	.	.	.	.
		Radiation, no chemotherapy	115	2	1.8	30	26.8	4	3.6	1	0.9	.	.
		Chemotherapy and radiation	437	22	5.1	202	46.8	11	2.6	8	1.8	5	1.1
		Unknown	48	2	4.3	11	23.9	.	.	2	4.3	.	.
Females	All cases		408	16	4.1	156	39.1	24	6.0	18	4.5	4	1.0
	Age at baseline	<18	99	1	1.0	34	34.7	3	3.1	1	1.0	.	.
		18-19	36	2	5.7	14	40.0	.	.	1	2.9	.	.
		20-24	106	4	4.0	38	36.9	5	4.8	3	2.9	1	1.0

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems

n=7 participants with no baseline information are not included

				Diabetes-pills (E.6/E.6) <sup>1</sup>		Diabetes-insulin (E.7/E.7) <sup>1</sup>		Growth hormone deficiency (E.8/E.8) <sup>1</sup>		Osteoporosis (E.10/E.10) <sup>1</sup>		Any hormonal problem <sup>2</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		1040	11	1.1	4	0.4	482	47.2	105	10.2	659	64.5
	Age at baseline	<18	246	1	0.4	1	0.4	141	58.0	20	8.1	166	69.2
		18-19	83	.	.	.	.	53	66.3	5	6.2	59	73.8
		20-24	291	3	1.0	1	0.3	142	49.7	31	10.8	184	64.1
		25-29	252	5	2.0	.	.	104	42.1	25	10.2	155	62.2
		30-34	131	1	0.8	1	0.8	39	30.2	22	16.9	80	62.0
		35+	37	1	2.8	1	2.7	3	8.1	2	5.4	15	40.5
	Years since diagnosis	5-9	124	.	.	1	0.8	59	48.0	11	8.9	75	61.5
		10-14	355	1	0.3	.	.	173	49.9	32	9.1	231	66.2
		15-19	344	5	1.5	2	0.6	160	47.3	29	8.6	217	64.4
		20+	217	5	2.3	1	0.5	90	42.1	33	15.3	136	63.6
	Age at diagnosis	<1	28	.	.	.	.	8	28.6	2	7.1	10	37.0
		1-4	298	4	1.4	.	.	180	61.4	27	9.1	211	72.5
		5-9	422	5	1.2	3	0.7	221	53.6	46	11.1	289	70.1
		10-14	230	2	0.9	.	.	67	29.5	26	11.6	129	56.1
		15-20	62	.	.	1	1.6	6	9.7	4	6.5	20	32.3
	Treatment	Surgery only	8	1	12.5	.	.	2	25.0	.	.	3	37.5
		Chemotherapy, no radiation	53	.	.	.	.	8	15.1	1	1.9	12	23.1
		Radiation, no chemotherapy	208	.	.	1	0.5	70	34.7	13	6.3	111	55.0
		Chemotherapy and radiation	692	10	1.5	3	0.4	373	54.9	85	12.5	494	72.5
		Unknown	79	.	.	.	.	29	36.7	6	7.6	39	49.4
Males	All cases		632	5	0.8	2	0.3	312	49.8	63	10.1	401	64.4
	Age at baseline	<18	147	1	0.7	.	.	85	58.2	12	8.2	102	70.8
		18-19	47	.	.	.	.	31	67.4	3	6.5	33	71.7
		20-24	185	.	.	1	0.5	100	54.3	22	12.0	123	67.2
		25-29	157	4	2.6	.	.	70	45.2	17	11.1	93	60.0
		30-34	73	.	.	1	1.4	24	33.3	9	12.3	41	56.9
		35+	23	.	.	.	.	2	8.7	.	.	9	39.1
	Years since diagnosis	5-9	76	.	.	.	.	38	50.0	7	9.2	45	60.0
		10-14	208	1	0.5	.	.	106	51.7	20	9.7	140	68.3
		15-19	217	2	0.9	1	0.5	107	49.8	18	8.5	132	62.0
		20+	131	2	1.5	1	0.8	61	46.9	18	13.7	84	64.6
	Age at diagnosis	<1	16	.	.	.	.	5	31.3	1	6.3	6	40.0
		1-4	180	2	1.1	.	.	114	63.7	17	9.4	132	74.2
		5-9	267	3	1.1	2	0.8	144	54.8	30	11.4	182	69.7
		10-14	132	.	.	.	.	47	35.9	14	10.9	73	55.3
		15-20	37	.	.	.	.	2	5.4	1	2.7	8	21.6
	Treatment	Surgery only	5	.	.	.	.	2	40.0	.	.	2	40.0
		Chemotherapy, no radiation	27	.	.	.	.	2	7.4	1	3.7	6	23.1
		Radiation, no chemotherapy	115	.	.	.	.	39	34.2	8	7.0	57	50.9
		Chemotherapy and radiation	437	5	1.1	2	0.5	251	58.1	53	12.3	313	72.5
		Unknown	48	.	.	.	.	18	37.5	1	2.1	23	47.9
Females	All cases		408	6	1.5	2	0.5	170	42.9	42	10.4	258	64.7
	Age at baseline	<18	99	.	.	1	1.0	56	57.7	8	8.1	64	66.7
		18-19	36	.	.	.	.	22	64.7	2	5.7	26	76.5
		20-24	106	3	2.9	.	.	42	41.2	9	8.7	61	58.7

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included

				Overactive thyroid (E.1/E.1) <sup>1</sup>		Underactive thyroid (E.2/E.2) <sup>1</sup>		Thyroid nodules (E.3/E.3) <sup>1</sup>		Thyroid enlargement (E.4/E.4) <sup>1</sup>		Diabetes-diet (E.5/E.5) <sup>1</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
		25-29	95	2	2.2	44	47.3	9	9.6	8	8.5	.	.
		30-34	58	6	10.7	22	39.3	7	12.5	4	7.0	2	3.5
		35+	14	1	7.1	4	28.6	.	.	1	7.7	1	7.7
	Years since diagnosis	5-9	48	1	2.1	18	38.3	1	2.1	.	.	.	.
		10-14	147	6	4.2	49	33.8	6	4.2	6	4.1	.	.
		15-19	127	3	2.4	61	49.2	10	8.1	8	6.4	2	1.6
		20+	86	6	7.5	28	33.7	7	8.4	4	4.8	2	2.4
	Age at diagnosis	<1	12	.	.	1	8.3	.	.	.	.	.	.
		1-4	118	1	0.9	48	41.7	5	4.4	1	0.9	.	.
		5-9	155	6	4.1	65	43.3	12	8.1	9	5.9	2	1.3
		10-14	98	8	8.2	35	36.1	6	6.1	8	8.2	2	2.0
		15-20	25	1	4.0	7	28.0	1	4.2	.	.	.	.
	Treatment	Surgery only	3	.	.	.	.	.	.	.	.	.	.
		Chemotherapy, no radiation	26	.	.	3	11.5	.	.	.	.	.	.
		Radiation, no chemotherapy	93	1	1.1	32	36.0	9	10.1	8	8.9	.	.
		Chemotherapy and radiation	255	14	5.7	115	46.0	14	5.6	10	4.0	3	1.2
		Unknown	31	1	3.2	6	19.4	1	3.2	.	.	1	3.2

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included

			Diabetes-pills (E.6/E.6) <sup>1</sup>			Diabetes-insulin (E.7/E.7) <sup>1</sup>		Growth hormone deficiency (E.8/E.8) <sup>1</sup>		Osteoporosis (E.10/E.10) <sup>1</sup>		Any hormonal problem <sup>2</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
		25-29	95	1	1.1	.	.	34	37.0	8	8.6	62	66.0
		30-34	58	1	1.8	.	.	15	26.3	13	22.8	39	68.4
		35+	14	1	7.7	1	7.1	1	7.1	2	14.3	6	42.9
	Years since diagnosis	5-9	48	.	.	1	2.1	21	44.7	4	8.3	30	63.8
		10-14	147	.	.	.	.	67	47.2	12	8.3	91	63.2
		15-19	127	3	2.4	1	0.8	53	43.1	11	8.8	85	68.5
		20+	86	3	3.6	.	.	29	34.5	15	17.9	52	61.9
	Age at diagnosis	<1	12	.	.	.	.	3	25.0	1	8.3	4	33.3
		1-4	118	2	1.7	.	.	66	57.9	10	8.5	79	69.9
		5-9	155	2	1.3	1	0.7	77	51.7	16	10.5	107	70.9
		10-14	98	2	2.1	.	.	20	20.8	12	12.5	56	57.1
		15-20	25	.	.	1	4.0	4	16.0	3	12.0	12	48.0
	Treatment	Surgery only	3	1	33.3	.	.	.	.	.	.	1	33.3
		Chemotherapy, no radiation	26	.	.	.	.	6	23.1	.	.	6	23.1
		Radiation, no chemotherapy	93	.	.	1	1.1	31	35.2	5	5.5	54	60.0
		Chemotherapy and radiation	255	5	2.0	1	0.4	122	49.2	32	12.7	181	72.7
		Unknown	31	.	.	.	.	11	35.5	5	16.1	16	51.6

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included

				Overactive thyroid (E.1/E.1) <sup>1</sup>		Underactive thyroid (E.2/E.2) <sup>1</sup>		Thyroid nodules (E.3/E.3) <sup>1</sup>		Thyroid enlargement (E.4/E.4) <sup>1</sup>		Diabetes-diet (E.5/E.5) <sup>1</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		3107	150	4.9	900	29.2	276	9.0	226	7.4	43	1.4
	Age at baseline	<18	61	1	1.7	17	28.8	1	1.7	4	6.8	.	.
		18-19	62	2	3.3	8	13.1	5	8.1	5	8.1	1	1.6
		20-24	376	17	4.5	60	16.0	21	5.6	20	5.3	1	0.3
		25-29	798	25	3.2	210	26.5	46	5.8	52	6.6	11	1.4
		30-34	949	59	6.3	292	31.1	86	9.2	65	7.0	18	1.9
		35+	861	46	5.4	313	36.5	117	13.7	80	9.4	12	1.4
	Years since diagnosis	5-9	242	7	2.9	48	19.9	4	1.7	12	5.0	1	0.4
		10-14	947	40	4.3	252	26.9	44	4.7	43	4.6	12	1.3
		15-19	1010	55	5.5	317	31.6	94	9.4	77	7.7	14	1.4
		20+	908	48	5.4	283	31.4	134	14.9	94	10.5	16	1.8
	Age at diagnosis	1-4	84	3	3.6	18	21.4	8	9.6	9	10.8	1	1.2
		5-9	421	24	5.7	76	18.2	44	10.6	42	10.1	5	1.2
		10-14	1118	48	4.4	285	25.8	109	9.9	89	8.1	17	1.5
		15-20	1484	75	5.1	521	35.3	115	7.8	86	5.9	20	1.4
	Treatment	Surgery only	2	.	.	.	.	.	.	.	.	.	.
		Chemotherapy, no radiation	363	9	2.5	29	8.0	10	2.8	14	3.9	5	1.4
		Radiation, no chemotherapy	651	40	6.2	246	38.1	85	13.2	59	9.3	4	0.6
		Chemotherapy and radiation	1759	82	4.7	554	31.8	160	9.2	139	8.0	29	1.7
		Unknown	332	19	5.8	71	21.5	21	6.3	14	4.2	5	1.5
Males	All cases		1631	72	4.4	349	21.5	69	4.3	83	5.1	18	1.1
	Age at baseline	<18	46	1	2.2	14	31.1	1	2.2	2	4.4	.	.
		18-19	49	1	2.1	7	14.3	4	8.2	5	10.2	.	.
		20-24	239	11	4.6	30	12.6	10	4.2	10	4.2	1	0.4
		25-29	445	11	2.5	99	22.3	21	4.8	26	5.9	4	0.9
		30-34	480	25	5.2	102	21.4	20	4.2	24	5.1	7	1.5
		35+	372	23	6.3	97	26.2	13	3.6	16	4.3	6	1.6
	Years since diagnosis	5-9	138	2	1.5	21	15.3	3	2.2	4	2.9	1	0.7
		10-14	492	17	3.5	107	21.8	13	2.7	20	4.1	4	0.8
		15-19	539	28	5.2	122	22.7	23	4.3	28	5.2	6	1.1
		20+	462	25	5.5	99	21.6	30	6.6	31	6.8	7	1.5
	Age at diagnosis	1-4	63	3	4.8	15	23.8	5	8.1	6	9.7	1	1.6
		5-9	305	18	5.9	45	14.8	23	7.6	26	8.6	2	0.7
		10-14	579	17	3.0	108	18.8	27	4.7	25	4.4	6	1.0
		15-20	684	34	5.0	181	26.5	14	2.1	26	3.8	9	1.3
	Treatment	Surgery only	1	.	.	.	.	.	.	.	.	.	.
		Chemotherapy, no radiation	186	2	1.1	9	4.8	1	0.5	4	2.2	3	1.6
		Radiation, no chemotherapy	336	19	5.7	98	29.4	24	7.3	19	5.8	1	0.3
		Chemotherapy and radiation	911	39	4.3	216	23.8	39	4.3	54	6.0	12	1.3
		Unknown	197	12	6.2	26	13.3	5	2.5	6	3.0	2	1.0
Females	All cases		1476	78	5.4	551	37.8	207	14.2	143	9.8	25	1.7
	Age at baseline	<18	15	.	.	3	21.4	.	.	2	14.3	.	.
		18-19	13	1	8.3	1	8.3	1	7.7	.	.	1	7.7
		20-24	137	6	4.4	30	22.1	11	8.1	10	7.3	.	.
		25-29	353	14	4.0	111	31.8	25	7.2	26	7.5	7	2.0
		30-34	469	34	7.4	190	41.2	66	14.3	41	8.9	11	2.4

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems

n=7 participants with no baseline information are not included

				Diabetes-pills (E.6/E.6) <sup>1</sup>		Diabetes-insulin (E.7/E.7) <sup>1</sup>		Growth hormone deficiency (E.8/E.8) <sup>1</sup>		Osteoporosis (E.10/E.10) <sup>1</sup>		Any hormonal problem <sup>2</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		3107	40	1.3	34	1.1	33	1.1	99	3.2	1283	42.3
	Age at baseline	<18	61	.	.	1	1.7	6	10.0	1	1.7	24	40.7
		18-19	62	1	1.7	.	.	2	3.3	2	3.2	17	28.3
		20-24	376	1	0.3	.	.	10	2.8	11	2.9	108	29.7
		25-29	798	5	0.7	7	0.9	6	0.8	19	2.4	276	35.6
		30-34	949	15	1.6	14	1.5	6	0.7	33	3.5	421	45.5
		35+	861	18	2.1	12	1.4	3	0.4	33	3.9	437	51.6
	Years since diagnosis	5-9	242	2	0.9	.	.	4	1.8	5	2.1	70	30.0
		10-14	947	5	0.5	7	0.7	13	1.4	25	2.7	339	37.1
		15-19	1010	10	1.0	13	1.3	8	0.8	33	3.3	450	45.7
		20+	908	23	2.6	14	1.5	8	0.9	36	4.0	424	47.2
	Age at diagnosis	1-4	84	2	2.4	1	1.2	6	7.2	2	2.4	31	36.9
		5-9	421	2	0.5	2	0.5	14	3.4	14	3.3	143	34.7
		10-14	1118	14	1.3	16	1.4	9	0.8	42	3.8	435	39.9
		15-20	1484	22	1.5	15	1.0	4	0.3	41	2.8	674	46.6
	Treatment	Surgery only	2	.	.	.	.	.	.	.	.	.	.
		Chemotherapy, no radiation	363	10	2.8	2	0.6	3	0.8	9	2.5	69	19.7
		Radiation, no chemotherapy	651	7	1.2	7	1.1	2	0.3	9	1.4	335	53.4
		Chemotherapy and radiation	1759	19	1.1	23	1.3	21	1.2	67	3.8	772	44.8
		Unknown	332	4	1.2	2	0.6	7	2.1	14	4.2	107	32.6
Males	All cases		1631	28	1.8	14	0.9	19	1.2	33	2.0	521	32.8
	Age at baseline	<18	46	.	.	.	.	4	8.7	1	2.2	19	42.2
		18-19	49	1	2.1	.	.	2	4.3	2	4.1	14	29.8
		20-24	239	1	0.4	.	.	7	3.0	7	2.9	57	24.7
		25-29	445	3	0.7	3	0.7	2	0.5	10	2.3	132	30.6
		30-34	480	10	2.1	6	1.3	3	0.6	6	1.3	158	33.6
		35+	372	13	3.6	5	1.3	1	0.3	7	1.9	141	38.6
	Years since diagnosis	5-9	138	1	0.8	.	.	3	2.3	2	1.4	33	25.4
		10-14	492	4	0.8	3	0.6	7	1.5	12	2.4	146	30.7
		15-19	539	7	1.3	6	1.1	5	1.0	10	1.9	186	35.5
		20+	462	16	3.5	5	1.1	4	0.9	9	2.0	156	34.0
	Age at diagnosis	1-4	63	2	3.2	.	.	4	6.3	2	3.2	23	36.5
		5-9	305	1	0.3	.	.	10	3.3	9	3.0	89	29.9
		10-14	579	11	2.0	7	1.2	4	0.7	14	2.4	170	30.1
		15-20	684	14	2.1	7	1.0	1	0.2	8	1.2	239	36.0
	Treatment	Surgery only	1	.	.	.	.	.	.	.	.	.	.
		Chemotherapy, no radiation	186	7	3.9	2	1.1	2	1.1	.	.	22	12.2
		Radiation, no chemotherapy	336	6	1.9	2	0.6	1	0.3	3	0.9	138	42.9
		Chemotherapy and radiation	911	12	1.3	9	1.0	10	1.1	21	2.3	311	34.9
		Unknown	197	3	1.5	1	0.5	6	3.1	9	4.6	50	25.6
Females	All cases		1476	12	0.8	20	1.4	14	1.0	66	4.5	762	52.9
	Age at baseline	<18	15	.	.	1	7.1	2	14.3	.	.	5	35.7
		18-19	13	.	.	.	.	.	.	.	.	3	23.1
		20-24	137	.	.	.	.	3	2.3	4	2.9	51	38.3
		25-29	353	2	0.6	4	1.1	4	1.2	9	2.6	144	41.9
		30-34	469	5	1.1	8	1.7	3	0.7	27	5.8	263	57.8

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems

n=7 participants with no baseline information are not included

				Overactive thyroid (E.1/E.1) <sup>1</sup>		Underactive thyroid (E.2/E.2) <sup>1</sup>		Thyroid nodules (E.3/E.3) <sup>1</sup>		Thyroid enlargement (E.4/E.4) <sup>1</sup>		Diabetes-diet (E.5/E.5) <sup>1</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
		35+	489	23	4.8	216	44.4	104	21.4	64	13.3	6	1.2
	Years since diagnosis	5-9	104	5	4.8	27	26.0	1	1.0	8	7.7	.	.
		10-14	455	23	5.2	145	32.5	31	6.9	23	5.1	8	1.8
		15-19	471	27	5.8	195	41.8	71	15.3	49	10.7	8	1.7
		20+	446	23	5.2	184	41.5	104	23.5	63	14.2	9	2.0
	Age at diagnosis	1-4	21	.	.	3	14.3	3	14.3	3	14.3	.	.
		5-9	116	6	5.3	31	27.2	21	18.4	16	13.9	3	2.6
		10-14	539	31	5.9	177	33.4	82	15.4	64	12.1	11	2.1
		15-20	800	41	5.2	340	42.8	101	12.8	60	7.6	11	1.4
	Treatment	Surgery only	1	.	.	.	.	.	.	.	.	.	.
		Chemotherapy, no radiation	177	7	4.0	20	11.4	9	5.1	10	5.7	2	1.1
		Radiation, no chemotherapy	315	21	6.8	148	47.4	61	19.6	40	13.0	3	1.0
		Chemotherapy and radiation	848	43	5.2	338	40.4	121	14.5	85	10.2	17	2.0
		Unknown	135	7	5.3	45	33.6	16	11.9	8	6.0	3	2.2

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included

				Diabetes-pills (E.6/E.6) <sup>1</sup>		Diabetes-insulin (E.7/E.7) <sup>1</sup>		Growth hormone deficiency (E.8/E.8) <sup>1</sup>		Osteoporosis (E.10/E.10) <sup>1</sup>		Any hormonal problem <sup>2</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
		35+	489	5	1.0	7	1.4	2	0.4	26	5.3	296	61.4
	Years since diagnosis	5-9	104	1	1.0	.	.	1	1.0	3	2.9	37	35.9
		10-14	455	1	0.2	4	0.9	6	1.4	13	2.9	193	44.2
		15-19	471	3	0.7	7	1.5	3	0.7	23	4.9	264	57.3
		20+	446	7	1.6	9	2.0	4	0.9	27	6.1	268	60.9
	Age at diagnosis	1-4	21	.	.	1	4.8	2	10.0	.	.	8	38.1
		5-9	116	1	0.9	2	1.7	4	3.5	5	4.3	54	47.4
		10-14	539	3	0.6	9	1.7	5	1.0	28	5.2	265	50.5
		15-20	800	8	1.0	8	1.0	3	0.4	33	4.2	435	55.7
	Treatment	Surgery only	1	.	.	.	.	.	.	.	.	.	.
		Chemotherapy, no radiation	177	3	1.7	.	.	1	0.6	9	5.1	47	27.6
		Radiation, no chemotherapy	315	1	0.3	5	1.6	1	0.3	6	1.9	197	64.6
		Chemotherapy and radiation	848	7	0.8	14	1.7	11	1.3	46	5.5	461	55.4
		Unknown	135	1	0.8	1	0.7	1	0.8	5	3.7	57	42.9

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'

<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included



				Overactive thyroid (E.1/E.1) <sup>1</sup>		Underactive thyroid (E.2/E.2) <sup>1</sup>		Thyroid nodules (E.3/E.3) <sup>1</sup>		Thyroid enlargement (E.4/E.4) <sup>1</sup>		Diabetes-diet (E.5/E.5) <sup>1</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		2114	27	1.3	125	6.0	44	2.1	50	2.4	34	1.6
	Age at baseline	<18	212	1	0.5	8	3.8	1	0.5	1	0.5	1	0.5
		18-19	132	1	0.8	9	6.9	2	1.5	1	0.8	.	.
		20-24	469	6	1.3	27	5.8	5	1.1	10	2.2	9	1.9
		25-29	569	6	1.1	26	4.6	7	1.2	9	1.6	5	0.9
		30-34	483	6	1.3	33	6.9	18	3.8	15	3.1	11	2.3
		35+	249	7	2.8	22	8.9	11	4.4	14	5.6	8	3.3
	Years since diagnosis	5-9	144	1	0.7	3	2.1	.	.	.	.	1	0.7
		10-14	672	7	1.1	31	4.7	11	1.7	9	1.4	8	1.2
		15-19	730	9	1.2	50	6.9	13	1.8	22	3.0	10	1.4
		20+	568	10	1.8	41	7.3	20	3.6	19	3.4	15	2.7
	Age at diagnosis	<1	15	.	.	.	.	1	6.7	.	.	.	.
		1-4	344	3	0.9	22	6.4	1	0.3	2	0.6	3	0.9
		5-9	647	11	1.7	38	5.9	17	2.6	20	3.1	9	1.4
		10-14	674	8	1.2	31	4.7	11	1.6	14	2.1	10	1.5
		15-20	434	5	1.2	34	7.9	14	3.3	14	3.3	12	2.8
	Treatment	Surgery only	16	.	.	.	.	.	.	1	6.3	.	.
		Chemotherapy, no radiation	1075	11	1.0	27	2.5	16	1.5	18	1.7	18	1.7
		Radiation, no chemotherapy	38	.	.	5	13.2	1	2.6	1	2.6	.	.
		Chemotherapy and radiation	766	11	1.5	82	10.8	24	3.2	24	3.2	13	1.7
		Unknown	219	5	2.3	11	5.1	3	1.4	6	2.8	3	1.4
Males	All cases		1436	14	1.0	66	4.6	13	0.9	18	1.3	15	1.1
	Age at baseline	<18	146	1	0.7	6	4.1	.	.	.	.	1	0.7
		18-19	97	.	.	6	6.3	1	1.0	.	.	.	.
		20-24	304	3	1.0	13	4.3	.	.	1	0.3	3	1.0
		25-29	405	5	1.2	13	3.3	1	0.3	6	1.5	1	0.2
		30-34	319	2	0.6	13	4.1	6	1.9	5	1.6	6	1.9
		35+	165	3	1.8	15	9.1	5	3.0	6	3.6	4	2.5
	Years since diagnosis	5-9	109	1	0.9	2	1.8	.	.	.	.	1	0.9
		10-14	457	3	0.7	15	3.3	3	0.7	4	0.9	4	0.9
		15-19	480	6	1.3	25	5.3	5	1.1	9	1.9	2	0.4
		20+	390	4	1.0	24	6.2	5	1.3	5	1.3	8	2.1
	Age at diagnosis	<1	5	.	.	.	.	.	.	.	.	.	.
		1-4	232	2	0.9	15	6.5	.	.	.	.	.	.
		5-9	451	4	0.9	18	4.0	4	0.9	5	1.1	4	0.9
		10-14	463	4	0.9	17	3.7	2	0.4	6	1.3	5	1.1
		15-20	285	4	1.4	16	5.7	7	2.5	7	2.5	6	2.1
	Treatment	Surgery only	13	.	.	.	.	.	.	1	7.7	.	.
		Chemotherapy, no radiation	727	6	0.8	9	1.3	4	0.6	5	0.7	8	1.1
		Radiation, no chemotherapy	28	.	.	5	17.9	1	3.6	1	3.6	.	.
		Chemotherapy and radiation	511	5	1.0	44	8.7	8	1.6	10	2.0	6	1.2
		Unknown	157	3	1.9	8	5.2	.	.	1	0.6	1	0.6
Females	All cases		678	13	1.9	59	8.8	31	4.6	32	4.8	19	2.8
	Age at baseline	<18	66	.	.	2	3.0	1	1.5	1	1.5	.	.
		18-19	35	1	2.9	3	8.6	1	2.9	1	2.9	.	.
		20-24	165	3	1.8	14	8.6	5	3.1	9	5.5	6	3.7

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems

n=7 participants with no baseline information are not included

				Diabetes-pills (E.6/E.6) <sup>1</sup>		Diabetes-insulin (E.7/E.7) <sup>1</sup>		Growth hormone deficiency (E.8/E.8) <sup>1</sup>		Osteoporosis (E.10/E.10) <sup>1</sup>		Any hormonal problem <sup>2</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		2114	24	1.2	36	1.7	63	3.0	59	2.8	326	15.8
	Age at baseline	<18	212	.	.	2	0.9	13	6.1	4	1.9	27	13.0
		18-19	132	.	.	1	0.8	9	7.0	2	1.5	17	13.4
		20-24	469	4	0.9	10	2.2	21	4.6	9	1.9	69	15.0
		25-29	569	3	0.5	7	1.2	11	2.0	20	3.5	73	13.1
		30-34	483	8	1.7	10	2.1	8	1.7	14	2.9	82	17.6
		35+	249	9	3.7	6	2.4	1	0.4	10	4.0	58	23.9
	Years since diagnosis	5-9	144	.	.	2	1.4	.	.	.	.	7	5.0
		10-14	672	4	0.6	12	1.8	18	2.7	19	2.9	90	13.8
		15-19	730	7	1.0	10	1.4	30	4.2	26	3.6	125	17.5
		20+	568	13	2.3	12	2.1	15	2.7	14	2.5	104	18.8
	Age at diagnosis	<1	15	.	.	.	.	2	13.3	.	.	3	20.0
		1-4	344	2	0.6	3	0.9	30	8.8	5	1.5	51	15.2
		5-9	647	2	0.3	6	0.9	22	3.4	15	2.3	98	15.4
		10-14	674	9	1.4	16	2.4	9	1.4	22	3.3	92	14.1
		15-20	434	11	2.6	11	2.5	.	.	17	3.9	82	19.5
	Treatment	Surgery only	16	.	.	.	.	.	.	.	.	1	6.3
		Chemotherapy, no radiation	1075	15	1.4	19	1.8	11	1.0	29	2.7	120	11.4
		Radiation, no chemotherapy	38	.	.	1	2.6	.	.	3	7.9	10	27.8
		Chemotherapy and radiation	766	8	1.1	13	1.7	47	6.3	22	2.9	163	22.0
		Unknown	219	1	0.5	3	1.4	5	2.3	5	2.3	32	14.8
Males	All cases		1436	13	0.9	20	1.4	41	2.9	30	2.1	176	12.6
	Age at baseline	<18	146	.	.	.	.	9	6.2	3	2.1	17	12.1
		18-19	97	.	.	1	1.0	4	4.3	2	2.1	10	10.8
		20-24	304	2	0.7	3	1.0	16	5.3	4	1.3	33	11.0
		25-29	405	1	0.3	4	1.0	7	1.8	10	2.5	41	10.4
		30-34	319	6	1.9	9	2.8	5	1.6	7	2.2	44	14.3
		35+	165	4	2.5	3	1.8	.	.	4	2.4	31	19.1
	Years since diagnosis	5-9	109	.	.	.	.	.	.	.	.	4	3.7
		10-14	457	3	0.7	5	1.1	13	2.9	9	2.0	46	10.4
		15-19	480	3	0.6	6	1.3	19	4.1	13	2.7	67	14.3
		20+	390	7	1.8	9	2.3	9	2.3	8	2.1	59	15.6
	Age at diagnosis	<1	5	.	.	.	.	.	.	.	.	.	.
		1-4	232	.	.	.	.	21	9.1	4	1.7	31	13.8
		5-9	451	.	.	4	0.9	13	2.9	9	2.0	51	11.5
		10-14	463	8	1.8	10	2.2	7	1.6	12	2.6	53	11.8
		15-20	285	5	1.8	6	2.1	.	.	5	1.8	41	14.8
	Treatment	Surgery only	13	.	.	.	.	.	.	.	.	1	7.7
		Chemotherapy, no radiation	727	8	1.1	9	1.2	8	1.1	16	2.2	57	8.0
		Radiation, no chemotherapy	28	.	.	1	3.6	.	.	1	3.6	8	29.6
		Chemotherapy and radiation	511	4	0.8	8	1.6	30	6.1	11	2.2	91	18.5
		Unknown	157	1	0.6	2	1.3	3	1.9	2	1.3	19	12.3
Females	All cases		678	11	1.6	16	2.4	22	3.3	29	4.3	150	22.6
	Age at baseline	<18	66	.	.	2	3.0	4	6.1	1	1.5	10	15.2
		18-19	35	.	.	.	.	5	14.3	.	.	7	20.6
		20-24	165	2	1.2	7	4.3	5	3.1	5	3.1	36	22.4

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included

				Overactive thyroid (E.1/E.1) <sup>1</sup>		Underactive thyroid (E.2/E.2) <sup>1</sup>		Thyroid nodules (E.3/E.3) <sup>1</sup>		Thyroid enlargement (E.4/E.4) <sup>1</sup>		Diabetes-diet (E.5/E.5) <sup>1</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
		25-29	164	1	0.6	13	8.0	6	3.7	3	1.8	4	2.4
		30-34	164	4	2.5	20	12.3	12	7.4	10	6.1	5	3.1
		35+	84	4	4.8	7	8.4	6	7.2	8	9.6	4	4.9
	Years since diagnosis	5-9	35	.	.	1	2.9	.	.	.	.	.	.
		10-14	215	4	1.9	16	7.5	8	3.8	5	2.3	4	1.9
		15-19	250	3	1.2	25	10.0	8	3.2	13	5.2	8	3.2
		20+	178	6	3.4	17	9.7	15	8.5	14	8.0	7	4.0
	Age at diagnosis	<1	10	.	.	.	.	1	10.0	.	.	.	.
		1-4	112	1	0.9	7	6.3	1	0.9	2	1.8	3	2.7
		5-9	196	7	3.6	20	10.3	13	6.6	15	7.7	5	2.6
		10-14	211	4	1.9	14	6.7	9	4.3	8	3.8	5	2.4
		15-20	149	1	0.7	18	12.2	7	4.8	7	4.7	6	4.1
	Treatment	Surgery only	3	.	.	.	.	.	.	.	.	.	.
		Chemotherapy, no radiation	348	5	1.4	18	5.2	12	3.5	13	3.8	10	2.9
		Radiation, no chemotherapy	10	.	.	.	.	.	.	.	.	.	.
		Chemotherapy and radiation	255	6	2.4	38	15.0	16	6.3	14	5.5	7	2.8
		Unknown	62	2	3.2	3	4.9	3	4.8	5	8.1	2	3.2

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'

<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included

				Diabetes-pills (E.6/E.6) <sup>1</sup>		Diabetes-insulin (E.7/E.7) <sup>1</sup>		Growth hormone deficiency (E.8/E.8) <sup>1</sup>		Osteoporosis (E.10/E.10) <sup>1</sup>		Any hormonal problem <sup>2</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
		25-29	164	2	1.2	3	1.8	4	2.5	10	6.1	32	19.8
		30-34	164	2	1.2	1	0.6	3	1.8	7	4.3	38	23.9
		35+	84	5	6.1	3	3.6	1	1.3	6	7.2	27	33.3
	Years since diagnosis	5-9	35	.	.	2	5.7	.	.	.	.	3	9.1
		10-14	215	1	0.5	7	3.3	5	2.4	10	4.7	44	20.9
		15-19	250	4	1.6	4	1.6	11	4.4	13	5.3	58	23.7
		20+	178	6	3.4	3	1.7	6	3.4	6	3.4	45	25.9
	Age at diagnosis	<1	10	.	.	.	.	2	20.0	.	.	3	30.0
		1-4	112	2	1.8	3	2.7	9	8.0	1	0.9	20	18.0
		5-9	196	2	1.0	2	1.0	9	4.6	6	3.1	47	24.2
		10-14	211	1	0.5	6	2.9	2	1.0	10	4.8	39	19.1
		15-20	149	6	4.1	5	3.4	.	.	12	8.1	41	28.5
	Treatment	Surgery only	3	.	.	.	.	.	.	.	.	.	.
		Chemotherapy, no radiation	348	7	2.0	10	2.9	3	0.9	13	3.8	63	18.5
		Radiation, no chemotherapy	10	.	.	.	.	.	.	2	20.0	2	22.2
		Chemotherapy and radiation	255	4	1.6	5	2.0	17	6.8	11	4.3	72	28.9
		Unknown	62	.	.	1	1.6	2	3.2	3	4.8	13	21.0

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'

<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included

				Overactive thyroid (E.1/E.1) <sup>1</sup>		Underactive thyroid (E.2/E.2) <sup>1</sup>		Thyroid nodules (E.3/E.3) <sup>1</sup>		Thyroid enlargement (E.4/E.4) <sup>1</sup>		Diabetes-diet (E.5/E.5) <sup>1</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		2274	13	0.6	45	2.0	15	0.7	33	1.5	19	0.8
	Age at baseline	<18	833	4	0.5	9	1.1	4	0.5	3	0.4	3	0.4
		18-19	306	3	1.0	5	1.6	1	0.3	4	1.3	.	.
		20-24	669	1	0.1	13	1.9	3	0.4	10	1.5	7	1.0
		25-29	374	5	1.3	16	4.3	6	1.6	13	3.6	9	2.4
		30-34	74	.	.	2	2.7	1	1.4	2	2.7	.	.
		35+	18	.	.	.	.	.	.	1	5.6	.	.
	Years since diagnosis	5-9	176	1	0.6	1	0.6	.	.	.	.	.	.
		10-14	740	4	0.5	12	1.6	5	0.7	5	0.7	3	0.4
		15-19	760	4	0.5	11	1.4	3	0.4	12	1.6	4	0.5
		20+	598	4	0.7	21	3.5	7	1.2	16	2.7	12	2.0
	Age at diagnosis	<1	330	1	0.3	6	1.8	.	.	2	0.6	2	0.6
		1-4	1395	5	0.4	23	1.7	10	0.7	19	1.4	13	0.9
		5-9	468	7	1.5	14	3.0	5	1.1	9	1.9	3	0.6
		10-14	58	.	.	2	3.4	.	.	2	3.4	1	1.7
		15-20	23	.	.	.	.	.	.	1	4.3	.	.
	Treatment	Surgery only	34	.	.	.	.	.	.	.	.	.	.
		Chemotherapy, no radiation	869	3	0.3	9	1.0	.	.	5	0.6	5	0.6
		Radiation, no chemotherapy	4	.	.	.	.	.	.	.	.	.	.
		Chemotherapy and radiation	1153	10	0.9	33	2.9	14	1.2	26	2.3	12	1.0
		Unknown	214	.	.	3	1.4	1	0.5	2	0.9	2	0.9
Males	All cases		1020	2	0.2	11	1.1	3	0.3	7	0.7	6	0.6
	Age at baseline	<18	404	1	0.2	4	1.0	1	0.2	2	0.5	2	0.5
		18-19	127	.	.	.	.	.	.	.	.	.	.
		20-24	285	.	.	5	1.8	.	.	2	0.7	2	0.7
		25-29	166	1	0.6	2	1.2	2	1.2	3	1.9	2	1.2
		30-34	30	.	.	.	.	.	.	.	.	.	.
		35+	8	.	.	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	79	.	.	.	.	.	.	.	.	.	.
		10-14	334	1	0.3	4	1.2	1	0.3	2	0.6	1	0.3
		15-19	336	.	.	3	0.9	.	.	1	0.3	2	0.6
		20+	271	1	0.4	4	1.5	2	0.7	4	1.5	3	1.1
	Age at diagnosis	<1	168	1	0.6	1	0.6	.	.	1	0.6	2	1.2
		1-4	629	.	.	8	1.3	2	0.3	5	0.8	4	0.6
		5-9	193	1	0.5	2	1.0	1	0.5	1	0.5	.	.
		10-14	21	.	.	.	.	.	.	.	.	.	.
		15-20	9	.	.	.	.	.	.	.	.	.	.
	Treatment	Surgery only	18	.	.	.	.	.	.	.	.	.	.
		Chemotherapy, no radiation	395	1	0.3	.	.	.	.	.	.	1	0.3
		Chemotherapy and radiation	499	1	0.2	11	2.2	3	0.6	7	1.4	4	0.8
		Unknown	108	.	.	.	.	.	.	.	.	1	0.9
Females	All cases		1254	11	0.9	34	2.7	12	1.0	26	2.1	13	1.0
	Age at baseline	<18	429	3	0.7	5	1.2	3	0.7	1	0.2	1	0.2
		18-19	179	3	1.7	5	2.8	1	0.6	4	2.2	.	.
		20-24	384	1	0.3	8	2.1	3	0.8	8	2.1	5	1.3
		25-29	208	4	1.9	14	6.8	4	1.9	10	4.9	7	3.4

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems

n=7 participants with no baseline information are not included

				Diabetes-pills (E.6/E.6) <sup>1</sup>		Diabetes-insulin (E.7/E.7) <sup>1</sup>		Growth hormone deficiency (E.8/E.8) <sup>1</sup>		Osteoporosis (E.10/E.10) <sup>1</sup>		Any hormonal problem <sup>2</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
<b>Both sexes</b>	<b>All cases</b>		<b>2274</b>	<b>11</b>	<b>0.5</b>	<b>23</b>	<b>1.0</b>	<b>49</b>	<b>2.2</b>	<b>43</b>	<b>1.9</b>	<b>187</b>	<b>8.4</b>
	<b>Age at baseline</b>	<18	833	1	0.1	4	0.5	16	1.9	10	1.2	42	5.1
		18-19	306	.	.	2	0.7	6	2.0	5	1.6	22	7.2
		20-24	669	3	0.5	6	0.9	13	2.0	11	1.7	54	8.3
		25-29	374	5	1.4	9	2.4	13	3.5	15	4.0	59	16.2
		30-34	74	2	2.7	2	2.8	.	.	2	2.7	8	11.0
		35+	18	.	.	.	.	1	5.9	.	.	2	11.8
	<b>Years since diagnosis</b>	5-9	176	.	.	.	.	2	1.1	1	0.6	3	1.7
		10-14	740	1	0.1	5	0.7	16	2.2	11	1.5	50	6.8
		15-19	760	2	0.3	7	0.9	15	2.0	12	1.6	55	7.4
		20+	598	8	1.4	11	1.9	16	2.7	19	3.2	79	13.6
	<b>Age at diagnosis</b>	<1	330	.	.	2	0.6	7	2.1	5	1.5	20	6.1
		1-4	1395	8	0.6	15	1.1	27	2.0	25	1.8	109	8.0
		5-9	468	3	0.6	6	1.3	14	3.0	12	2.6	51	11.1
		10-14	58	.	.	.	.	1	1.7	1	1.7	6	10.3
		15-20	23	.	.	.	.	.	.	.	.	1	4.5
	<b>Treatment</b>	Surgery only	34	.	.	.	.	2	6.1	1	2.9	3	9.1
		Chemotherapy, no radiation	869	.	.	3	0.3	8	0.9	9	1.0	36	4.2
		Radiation, no chemotherapy	4	.	.	.	.	.	.	.	.	.	.
		Chemotherapy and radiation	1153	10	0.9	18	1.6	35	3.1	30	2.6	135	11.9
		Unknown	214	1	0.5	2	0.9	4	1.9	3	1.4	13	6.2
<b>Males</b>	<b>All cases</b>		<b>1020</b>	<b>3</b>	<b>0.3</b>	<b>8</b>	<b>0.8</b>	<b>16</b>	<b>1.6</b>	<b>9</b>	<b>0.9</b>	<b>51</b>	<b>5.1</b>
	<b>Age at baseline</b>	<18	404	1	0.2	2	0.5	6	1.5	3	0.7	17	4.3
		18-19	127	.	.	.	.	1	0.8	2	1.6	3	2.4
		20-24	285	1	0.4	2	0.7	5	1.8	2	0.7	15	5.4
		25-29	166	1	0.6	4	2.4	4	2.5	1	0.6	15	9.4
		30-34	30	.	.	.	.	.	.	1	3.3	1	3.3
		35+	8	.	.	.	.	.	.	.	.	.	.
	<b>Years since diagnosis</b>	5-9	79	.	.	.	.	.	.	.	.	.	.
		10-14	334	1	0.3	2	0.6	5	1.5	3	0.9	15	4.6
		15-19	336	1	0.3	2	0.6	5	1.5	4	1.2	15	4.5
		20+	271	1	0.4	4	1.5	6	2.2	2	0.7	21	8.0
	<b>Age at diagnosis</b>	<1	168	.	.	1	0.6	3	1.8	2	1.2	10	6.0
		1-4	629	3	0.5	4	0.6	10	1.6	5	0.8	31	5.0
		5-9	193	.	.	3	1.6	3	1.6	2	1.0	10	5.3
		10-14	21	.	.	.	.	.	.	.	.	.	.
		15-20	9	.	.	.	.	.	.	.	.	.	.
	<b>Treatment</b>	Surgery only	18	.	.	.	.	2	11.1	1	5.6	3	16.7
		Chemotherapy, no radiation	395	.	.	1	0.3	3	0.8	3	0.8	8	2.1
		Chemotherapy and radiation	499	3	0.6	6	1.2	9	1.8	5	1.0	36	7.3
		Unknown	108	.	.	1	0.9	2	1.9	.	.	4	3.8
<b>Females</b>	<b>All cases</b>		<b>1254</b>	<b>8</b>	<b>0.6</b>	<b>15</b>	<b>1.2</b>	<b>33</b>	<b>2.7</b>	<b>34</b>	<b>2.7</b>	<b>136</b>	<b>11.0</b>
	<b>Age at baseline</b>	<18	429	.	.	2	0.5	10	2.3	7	1.6	25	5.9
		18-19	179	.	.	2	1.1	5	2.8	3	1.7	19	10.7
		20-24	384	2	0.5	4	1.0	8	2.1	9	2.4	39	10.5
		25-29	208	4	2.0	5	2.4	9	4.4	14	6.8	44	21.5

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included

				Overactive thyroid (E.1/E.1) <sup>1</sup>		Underactive thyroid (E.2/E.2) <sup>1</sup>		Thyroid nodules (E.3/E.3) <sup>1</sup>		Thyroid enlargement (E.4/E.4) <sup>1</sup>		Diabetes-diet (E.5/E.5) <sup>1</sup>	
				All cases	N	%	N	%	N	%	N	%	%
		30-34	44	.	.	2	4.7	1	2.3	2	4.7	.	.
		35+	10	.	.	.	.	.	.	1	10.0	.	.
	Years since diagnosis	5-9	97	1	1.0	1	1.0	.	.	.	.	.	.
		10-14	406	3	0.7	8	2.0	4	1.0	3	0.7	2	0.5
		15-19	424	4	0.9	8	1.9	3	0.7	11	2.6	2	0.5
		20+	327	3	0.9	17	5.3	5	1.5	12	3.7	9	2.8
	Age at diagnosis	<1	162	.	.	5	3.1	.	.	1	0.6	.	.
		1-4	766	5	0.7	15	2.0	8	1.1	14	1.8	9	1.2
		5-9	275	6	2.2	12	4.4	4	1.5	8	2.9	3	1.1
		10-14	37	.	.	2	5.4	.	.	2	5.4	1	2.7
		15-20	14	.	.	.	.	.	.	1	7.1	.	.
	Treatment	Surgery only	16	.	.	.	.	.	.	.	.	.	.
		Chemotherapy, no radiation	474	2	0.4	9	1.9	.	.	5	1.1	4	0.8
		Radiation, no chemotherapy	4	.	.	.	.	.	.	.	.	.	.
		Chemotherapy and radiation	654	9	1.4	22	3.4	11	1.7	19	2.9	8	1.2
		Unknown	106	.	.	3	2.9	1	1.0	2	1.9	1	1.0

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included

				Diabetes-pills (E.6/E.6) <sup>1</sup>		Diabetes-insulin (E.7/E.7) <sup>1</sup>		Growth hormone deficiency (E.8/E.8) <sup>1</sup>		Osteoporosis (E.10/E.10) <sup>1</sup>		Any hormonal problem <sup>2</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
		30-34	44	2	4.7	2	4.8	.	.	1	2.3	7	16.3
		35+	10	.	.	.	.	1	11.1	.	.	2	22.2
	Years since diagnosis	5-9	97	.	.	.	.	2	2.1	1	1.0	3	3.1
		10-14	406	.	.	3	0.7	11	2.7	8	2.0	35	8.7
		15-19	424	1	0.2	5	1.2	10	2.4	8	1.9	40	9.6
		20+	327	7	2.2	7	2.2	10	3.1	17	5.3	58	18.2
	Age at diagnosis	<1	162	.	.	1	0.6	4	2.5	3	1.9	10	6.2
		1-4	766	5	0.7	11	1.4	17	2.2	20	2.6	78	10.4
		5-9	275	3	1.1	3	1.1	11	4.0	10	3.7	41	15.2
		10-14	37	.	.	.	.	1	2.7	1	2.7	6	16.2
		15-20	14	.	.	.	.	.	.	.	.	1	7.7
	Treatment	Surgery only	16	.	.	.	.	.	.	.	.	.	.
		Chemotherapy, no radiation	474	.	.	2	0.4	5	1.1	6	1.3	28	6.0
		Radiation, no chemotherapy	4	.	.	.	.	.	.	.	.	.	.
		Chemotherapy and radiation	654	7	1.1	12	1.8	26	4.0	25	3.9	99	15.4
		Unknown	106	1	1.0	1	1.0	2	1.9	3	2.9	9	8.7

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included



				Overactive thyroid (E.1/E.1) <sup>1</sup>		Underactive thyroid (E.2/E.2) <sup>1</sup>		Thyroid nodules (E.3/E.3) <sup>1</sup>		Thyroid enlargement (E.4/E.4) <sup>1</sup>		Diabetes-diet (E.5/E.5) <sup>1</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		1947	20	1.0	98	5.1	36	1.9	35	1.8	25	1.3
	Age at baseline	<18	956	4	0.4	35	3.7	9	0.9	11	1.2	3	0.3
		18-19	237	3	1.3	12	5.1	.	.	2	0.8	2	0.8
		20-24	540	8	1.5	26	4.9	14	2.6	13	2.4	14	2.6
		25-29	170	4	2.4	17	10.1	8	4.7	6	3.6	2	1.2
		30-34	36	1	2.8	6	17.1	5	13.9	2	5.6	4	11.1
		35+	8	.	.	2	25.0	.	.	1	12.5	.	.
	Years since diagnosis	5-9	160	.	.	5	3.1	.	.	1	0.6	.	.
		10-14	609	4	0.7	29	4.8	5	0.8	8	1.3	3	0.5
		15-19	640	6	0.9	30	4.7	11	1.7	12	1.9	7	1.1
		20+	538	10	1.9	34	6.4	20	3.8	14	2.6	15	2.8
	Age at diagnosis	<1	989	8	0.8	22	2.2	10	1.0	11	1.1	8	0.8
		1-4	760	10	1.3	54	7.2	21	2.8	17	2.2	11	1.5
		5-9	149	2	1.4	14	9.5	4	2.7	5	3.4	5	3.4
		10-14	30	.	.	7	23.3	.	.	2	6.9	.	.
		15-20	19	.	.	1	5.3	1	5.3	.	.	1	5.3
	Treatment	Surgery only	545	2	0.4	6	1.1	2	0.4	5	0.9	4	0.7
		Chemotherapy, no radiation	559	5	0.9	15	2.7	7	1.3	6	1.1	6	1.1
		Radiation, no chemotherapy	138	.	.	5	3.6	1	0.7	3	2.2	.	.
		Chemotherapy and radiation	531	11	2.1	66	12.5	21	4.0	16	3.0	14	2.6
		Unknown	174	2	1.1	6	3.5	5	2.9	5	2.9	1	0.6
Males	All cases		949	9	1.0	43	4.6	10	1.1	13	1.4	16	1.7
	Age at baseline	<18	478	3	0.6	16	3.4	3	0.6	6	1.3	3	0.6
		18-19	104	2	1.9	9	8.7	.	.	1	1.0	1	1.0
		20-24	272	3	1.1	8	3.0	3	1.1	4	1.5	8	3.0
		25-29	78	1	1.3	7	9.1	3	3.9	1	1.3	2	2.6
		30-34	14	.	.	1	7.1	1	7.1	.	.	2	14.3
		35+	3	.	.	2	66.7	.	.	1	33.3	.	.
	Years since diagnosis	5-9	75	.	.	2	2.7	.	.	1	1.3	.	.
		10-14	303	3	1.0	15	5.0	2	0.7	5	1.7	2	0.7
		15-19	308	4	1.3	13	4.2	3	1.0	4	1.3	5	1.6
		20+	263	2	0.8	13	5.0	5	1.9	3	1.1	9	3.4
	Age at diagnosis	<1	514	3	0.6	11	2.1	3	0.6	5	1.0	5	1.0
		1-4	342	4	1.2	23	6.8	6	1.8	4	1.2	8	2.3
		5-9	74	2	2.7	6	8.2	1	1.4	2	2.7	3	4.1
		10-14	13	.	.	2	15.4	.	.	2	16.7	.	.
		15-20	6	.	.	1	16.7	.	.	.	.	.	.
	Treatment	Surgery only	261	1	0.4	1	0.4	.	.	1	0.4	3	1.2
		Chemotherapy, no radiation	277	2	0.7	7	2.5	2	0.7	2	0.7	3	1.1
		Radiation, no chemotherapy	62	.	.	1	1.6	.	.	.	.	.	.
		Chemotherapy and radiation	259	5	1.9	31	12.0	7	2.7	7	2.7	10	3.9
		Unknown	90	1	1.1	3	3.3	1	1.1	3	3.3	.	.
Females	All cases		998	11	1.1	55	5.6	26	2.6	22	2.2	9	0.9
	Age at baseline	<18	478	1	0.2	19	4.0	6	1.3	5	1.1	.	.
		18-19	133	1	0.8	3	2.3	.	.	1	0.8	1	0.8
		20-24	268	5	1.9	18	6.8	11	4.2	9	3.4	6	2.2

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems

n=7 participants with no baseline information are not included

				Diabetes-pills (E.6/E.6) <sup>1</sup>		Diabetes-insulin (E.7/E.7) <sup>1</sup>		Growth hormone deficiency (E.8/E.8) <sup>1</sup>		Osteoporosis (E.10/E.10) <sup>1</sup>		Any hormonal problem <sup>2</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		1947	20	1.0	26	1.3	125	6.5	56	2.9	284	14.9
	Age at baseline	<18	956	3	0.3	6	0.6	60	6.3	19	2.0	105	11.2
		18-19	237	1	0.4	4	1.7	11	4.7	7	3.0	32	13.8
		20-24	540	10	1.9	11	2.0	35	6.6	22	4.1	93	17.7
		25-29	170	4	2.4	3	1.8	16	9.7	6	3.6	41	24.8
		30-34	36	2	5.9	2	5.6	3	8.8	2	5.6	11	32.4
		35+	8	.	.	.	.	.	.	.	.	2	25.0
	Years since diagnosis	5-9	160	.	.	1	0.6	11	6.9	8	5.0	21	13.4
		10-14	609	1	0.2	6	1.0	42	7.0	12	2.0	78	13.0
		15-19	640	8	1.3	7	1.1	38	6.0	19	3.0	89	14.3
		20+	538	11	2.1	12	2.2	34	6.5	17	3.2	96	18.3
	Age at diagnosis	<1	989	3	0.3	6	0.6	20	2.0	12	1.2	84	8.6
		1-4	760	11	1.5	15	2.0	83	11.1	33	4.4	146	19.7
		5-9	149	6	4.1	4	2.7	20	13.6	11	7.4	42	28.8
		10-14	30	.	.	.	.	2	7.1	.	.	8	28.6
		15-20	19	.	.	1	5.3	.	.	.	.	4	22.2
	Treatment	Surgery only	545	3	0.6	2	0.4	3	0.6	3	0.6	22	4.1
		Chemotherapy, no radiation	559	2	0.4	3	0.5	18	3.2	11	2.0	55	10.0
		Radiation, no chemotherapy	138	.	.	1	0.7	6	4.7	2	1.5	13	10.4
		Chemotherapy and radiation	531	15	2.9	16	3.0	92	17.5	38	7.2	177	33.9
		Unknown	174	.	.	4	2.3	6	3.5	2	1.1	17	9.9
Males	All cases		949	14	1.5	16	1.7	58	6.2	19	2.0	125	13.5
	Age at baseline	<18	478	2	0.4	3	0.6	33	7.0	9	1.9	55	11.7
		18-19	104	.	.	3	2.9	6	5.8	2	1.9	16	15.7
		20-24	272	6	2.3	8	3.0	12	4.5	7	2.6	34	12.9
		25-29	78	4	5.3	1	1.3	6	8.0	1	1.3	16	21.3
		30-34	14	2	15.4	1	7.1	1	7.7	.	.	2	15.4
		35+	3	.	.	.	.	.	.	.	.	2	66.7
	Years since diagnosis	5-9	75	.	.	.	.	7	9.5	5	6.7	12	16.2
		10-14	303	1	0.3	4	1.3	21	7.0	4	1.3	38	12.8
		15-19	308	3	1.0	5	1.6	20	6.6	7	2.3	40	13.4
		20+	263	10	3.9	7	2.7	10	3.9	3	1.1	35	13.6
	Age at diagnosis	<1	514	3	0.6	5	1.0	12	2.4	5	1.0	40	7.9
		1-4	342	6	1.8	8	2.3	32	9.5	9	2.7	59	17.6
		5-9	74	5	6.9	3	4.1	13	18.1	5	6.8	23	32.4
		10-14	13	.	.	.	.	1	9.1	.	.	2	18.2
		15-20	6	.	.	.	.	.	.	.	.	1	16.7
	Treatment	Surgery only	261	2	0.8	2	0.8	2	0.8	.	.	8	3.1
		Chemotherapy, no radiation	277	2	0.7	2	0.7	12	4.4	4	1.4	28	10.3
		Radiation, no chemotherapy	62	.	.	.	.	.	.	.	.	1	1.8
		Chemotherapy and radiation	259	10	3.9	11	4.3	40	15.6	14	5.4	80	31.4
		Unknown	90	.	.	1	1.1	4	4.4	1	1.1	8	8.9
Females	All cases		998	6	0.6	10	1.0	67	6.8	37	3.7	159	16.3
	Age at baseline	<18	478	1	0.2	3	0.6	27	5.7	10	2.1	50	10.6
		18-19	133	1	0.8	1	0.8	5	3.8	5	3.8	16	12.3
		20-24	268	4	1.5	3	1.1	23	8.7	15	5.6	59	22.5

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included

				Overactive thyroid (E.1/E.1) <sup>1</sup>		Underactive thyroid (E.2/E.2) <sup>1</sup>		Thyroid nodules (E.3/E.3) <sup>1</sup>		Thyroid enlargement (E.4/E.4) <sup>1</sup>		Diabetes-diet (E.5/E.5) <sup>1</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
		25-29	92	3	3.3	10	11.0	5	5.4	5	5.4	.	.
		30-34	22	1	4.5	5	23.8	4	18.2	2	9.1	2	9.1
		35+	5	.	.	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	85	.	.	3	3.5	.	.	.	.	.	.
		10-14	306	1	0.3	14	4.6	3	1.0	3	1.0	1	0.3
		15-19	332	2	0.6	17	5.1	8	2.4	8	2.4	2	0.6
		20+	275	8	2.9	21	7.8	15	5.5	11	4.0	6	2.2
	Age at diagnosis	<1	475	5	1.1	11	2.3	7	1.5	6	1.3	3	0.6
		1-4	418	6	1.4	31	7.5	15	3.6	13	3.1	3	0.7
		5-9	75	.	.	8	10.7	3	4.0	3	4.0	2	2.7
		10-14	17	.	.	5	29.4	.	.	.	.	.	.
		15-20	13	.	.	.	.	1	7.7	.	.	1	7.7
	Treatment	Surgery only	284	1	0.4	5	1.8	2	0.7	4	1.4	1	0.4
		Chemotherapy, no radiation	282	3	1.1	8	2.9	5	1.8	4	1.4	3	1.1
		Radiation, no chemotherapy	76	.	.	4	5.3	1	1.4	3	4.0	.	.
		Chemotherapy and radiation	272	6	2.2	35	13.0	14	5.2	9	3.3	4	1.5
		Unknown	84	1	1.2	3	3.6	4	4.8	2	2.4	1	1.2

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included

				Diabetes-pills (E.6/E.6) <sup>1</sup>		Diabetes-insulin (E.7/E.7) <sup>1</sup>		Growth hormone deficiency (E.8/E.8) <sup>1</sup>		Osteoporosis (E.10/E.10) <sup>1</sup>		Any hormonal problem <sup>2</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
		25-29	92	.	.	2	2.2	10	11.1	5	5.4	25	27.8
		30-34	22	.	.	1	4.5	2	9.5	2	9.1	9	42.9
		35+	5	.	.	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	85	.	.	1	1.2	4	4.7	3	3.6	9	10.8
		10-14	306	.	.	2	0.7	21	6.9	8	2.6	40	13.2
		15-19	332	5	1.5	2	0.6	18	5.5	12	3.6	49	15.1
		20+	275	1	0.4	5	1.8	24	8.9	14	5.1	61	22.8
	Age at diagnosis	<1	475	.	.	1	0.2	8	1.7	7	1.5	44	9.4
		1-4	418	5	1.2	7	1.7	51	12.4	24	5.8	87	21.4
		5-9	75	1	1.3	1	1.3	7	9.3	6	8.0	19	25.3
		10-14	17	.	.	.	.	1	5.9	.	.	6	35.3
		15-20	13	.	.	1	7.7	.	.	.	.	3	25.0
	Treatment	Surgery only	284	1	0.4	.	.	1	0.4	3	1.1	14	5.0
		Chemotherapy, no radiation	282	.	.	1	0.4	6	2.2	7	2.5	27	9.7
		Radiation, no chemotherapy	76	.	.	1	1.3	6	8.3	2	2.7	12	17.1
		Chemotherapy and radiation	272	5	1.9	5	1.8	52	19.3	24	8.9	97	36.3
		Unknown	84	.	.	3	3.6	2	2.4	1	1.2	9	11.0

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included

				Overactive thyroid (E.1/E.1) <sup>1</sup>		Underactive thyroid (E.2/E.2) <sup>1</sup>		Thyroid nodules (E.3/E.3) <sup>1</sup>		Thyroid enlargement (E.4/E.4) <sup>1</sup>		Diabetes-diet (E.5/E.5) <sup>1</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		1756	25	1.4	133	7.6	25	1.4	34	2.0	13	0.7
	Age at baseline	<18	341	4	1.2	20	5.9	3	0.9	6	1.8	.	.
		18-19	125	1	0.8	10	8.2	3	2.5	.	.	1	0.8
		20-24	425	3	0.7	33	7.8	6	1.4	11	2.6	1	0.2
		25-29	392	8	2.1	36	9.2	6	1.5	8	2.0	5	1.3
		30-34	297	9	3.0	26	8.8	6	2.0	5	1.7	2	0.7
		35+	176	.	.	8	4.6	1	0.6	4	2.3	4	2.3
	Years since diagnosis	5-9	182	2	1.1	7	3.8	.	.	.	.	1	0.5
		10-14	521	7	1.4	40	7.7	7	1.4	10	1.9	2	0.4
		15-19	540	10	1.9	32	6.0	6	1.1	9	1.7	5	0.9
		20+	513	6	1.2	54	10.6	12	2.4	15	2.9	5	1.0
	Age at diagnosis	<1	124	.	.	3	2.4	1	0.8	1	0.8	1	0.8
		1-4	560	8	1.4	49	8.8	11	2.0	15	2.7	1	0.2
		5-9	397	3	0.8	40	10.2	8	2.0	7	1.8	2	0.5
		10-14	346	9	2.6	28	8.1	3	0.9	5	1.4	2	0.6
		15-20	329	5	1.5	13	4.0	2	0.6	6	1.8	7	2.1
	Treatment	Surgery only	171	1	0.6	2	1.2	.	.	1	0.6	1	0.6
		Chemotherapy, no radiation	359	2	0.6	5	1.4	2	0.6	2	0.6	3	0.8
		Radiation, no chemotherapy	63	2	3.2	3	4.8	2	3.2	.	.	.	.
		Chemotherapy and radiation	971	18	1.9	115	11.9	20	2.1	29	3.0	6	0.6
		Unknown	192	2	1.1	8	4.2	1	0.5	2	1.0	3	1.6
Males	All cases		949	11	1.2	56	5.9	9	1.0	12	1.3	5	0.5
	Age at baseline	<18	192	3	1.6	9	4.7	2	1.0	2	1.0	.	.
		18-19	66	.	.	4	6.3	3	4.8	.	.	1	1.5
		20-24	242	1	0.4	16	6.6	3	1.3	5	2.1	.	.
		25-29	207	2	1.0	16	7.8	.	.	3	1.5	1	0.5
		30-34	158	5	3.2	10	6.4	1	0.6	1	0.6	1	0.6
		35+	84	.	.	1	1.2	.	.	1	1.2	2	2.4
	Years since diagnosis	5-9	100	1	1.0	3	3.0	.	.	.	.	.	.
		10-14	288	5	1.7	18	6.3	6	2.1	5	1.7	1	0.3
		15-19	281	3	1.1	14	5.1	2	0.7	3	1.1	2	0.7
		20+	280	2	0.7	21	7.5	1	0.4	4	1.4	2	0.7
	Age at diagnosis	<1	52	.	.	.	.	.	.	.	.	.	.
		1-4	330	4	1.2	27	8.3	5	1.5	6	1.8	1	0.3
		5-9	224	.	.	13	5.9	4	1.8	2	0.9	.	.
		10-14	186	4	2.2	14	7.6	.	.	2	1.1	1	0.5
		15-20	157	3	1.9	2	1.3	.	.	2	1.3	3	1.9
	Treatment	Surgery only	74	1	1.4	.	.	.	.	.	.	1	1.4
		Chemotherapy, no radiation	211	1	0.5	2	1.0	.	.	.	.	1	0.5
		Radiation, no chemotherapy	32	1	3.1	.	.	1	3.1	.	.	.	.
		Chemotherapy and radiation	521	7	1.4	52	10.1	8	1.6	11	2.1	3	0.6
		Unknown	111	1	0.9	2	1.8	.	.	1	0.9	.	.
Females	All cases		807	14	1.7	77	9.6	16	2.0	22	2.8	8	1.0
	Age at baseline	<18	149	1	0.7	11	7.4	1	0.7	4	2.7	.	.
		18-19	59	1	1.7	6	10.3	.	.	.	.	.	.
		20-24	183	2	1.1	17	9.4	3	1.7	6	3.3	1	0.6

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems

n=7 participants with no baseline information are not included

				Diabetes-pills (E.6/E.6) <sup>1</sup>		Diabetes-insulin (E.7/E.7) <sup>1</sup>		Growth hormone deficiency (E.8/E.8) <sup>1</sup>		Osteoporosis (E.10/E.10) <sup>1</sup>		Any hormonal problem <sup>2</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
<b>Both sexes</b>	<b>All cases</b>		<b>1756</b>	<b>3</b>	<b>0.2</b>	<b>12</b>	<b>0.7</b>	<b>175</b>	<b>10.2</b>	<b>72</b>	<b>4.1</b>	<b>346</b>	<b>20.2</b>
	<b>Age at baseline</b>	<18	341	.	.	1	0.3	52	15.2	14	4.1	69	20.5
		18-19	125	.	.	.	.	17	14.0	6	4.9	28	23.1
		20-24	425	.	.	1	0.2	53	12.8	19	4.5	88	21.4
		25-29	392	1	0.3	5	1.3	43	11.3	20	5.1	89	23.3
		30-34	297	.	.	3	1.0	9	3.1	6	2.0	50	17.1
		35+	176	2	1.2	2	1.1	1	0.6	7	4.0	22	12.8
	<b>Years since diagnosis</b>	5-9	182	.	.	1	0.6	18	10.2	8	4.4	30	17.0
		10-14	521	.	.	5	1.0	63	12.3	24	4.7	110	21.5
		15-19	540	1	0.2	1	0.2	46	8.7	22	4.1	98	18.6
		20+	513	2	0.4	5	1.0	48	9.5	18	3.5	108	21.5
	<b>Age at diagnosis</b>	<1	124	.	.	1	0.8	6	5.0	2	1.6	11	9.2
		1-4	560	.	.	1	0.2	89	16.2	25	4.5	131	23.9
		5-9	397	.	.	2	0.5	58	14.8	21	5.4	97	25.0
		10-14	346	1	0.3	3	0.9	19	5.6	14	4.1	67	19.8
		15-20	329	2	0.6	5	1.5	3	0.9	10	3.1	40	12.5
	<b>Treatment</b>	Surgery only	171	1	0.6	.	.	2	1.2	1	0.6	8	4.8
		Chemotherapy, no radiation	359	.	.	2	0.6	2	0.6	5	1.4	17	4.8
		Radiation, no chemotherapy	63	.	.	2	3.2	1	1.7	1	1.6	9	14.8
		Chemotherapy and radiation	971	1	0.1	5	0.5	157	16.5	53	5.5	279	29.4
		Unknown	192	1	0.5	3	1.6	13	6.8	12	6.3	33	17.4
<b>Males</b>	<b>All cases</b>		<b>949</b>	<b>1</b>	<b>0.1</b>	<b>4</b>	<b>0.4</b>	<b>100</b>	<b>10.7</b>	<b>30</b>	<b>3.2</b>	<b>166</b>	<b>17.9</b>
	<b>Age at baseline</b>	<18	192	.	.	1	0.5	29	15.1	7	3.6	36	18.8
		18-19	66	.	.	.	.	10	15.6	3	4.5	15	23.1
		20-24	242	.	.	1	0.4	26	11.1	9	3.8	45	19.3
		25-29	207	.	.	2	1.0	29	14.1	8	3.9	43	21.2
		30-34	158	.	.	.	.	6	3.9	1	0.6	21	13.6
		35+	84	1	1.2	.	.	.	.	2	2.4	6	7.4
	<b>Years since diagnosis</b>	5-9	100	.	.	1	1.0	11	11.6	6	6.0	18	18.8
		10-14	288	.	.	3	1.0	37	12.9	9	3.1	59	20.6
		15-19	281	.	.	.	.	23	8.4	9	3.2	42	15.4
		20+	280	1	0.4	.	.	29	10.5	6	2.2	47	17.2
	<b>Age at diagnosis</b>	<1	52	.	.	.	.	4	7.8	1	1.9	5	9.8
		1-4	330	.	.	1	0.3	48	14.8	13	4.0	67	20.6
		5-9	224	.	.	.	.	30	13.5	6	2.7	43	19.5
		10-14	186	.	.	2	1.1	16	8.8	7	3.8	37	20.4
		15-20	157	1	0.7	1	0.6	2	1.3	3	1.9	14	9.3
	<b>Treatment</b>	Surgery only	74	1	1.4	.	.	2	2.9	.	.	4	5.8
		Chemotherapy, no radiation	211	.	.	.	.	2	1.0	2	1.0	7	3.4
		Radiation, no chemotherapy	32	.	.	1	3.1	.	.	1	3.1	3	9.7
		Chemotherapy and radiation	521	.	.	2	0.4	86	16.8	24	4.6	137	26.7
		Unknown	111	.	.	1	0.9	10	9.1	3	2.7	15	13.8
<b>Females</b>	<b>All cases</b>		<b>807</b>	<b>2</b>	<b>0.3</b>	<b>8</b>	<b>1.0</b>	<b>75</b>	<b>9.5</b>	<b>42</b>	<b>5.2</b>	<b>180</b>	<b>22.8</b>
	<b>Age at baseline</b>	<18	149	.	.	.	.	23	15.4	7	4.7	33	22.8
		18-19	59	.	.	.	.	7	12.3	3	5.3	13	23.2
		20-24	183	.	.	.	.	27	15.1	10	5.5	43	24.0

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included

				Overactive thyroid (E.1/E.1) <sup>1</sup>		Underactive thyroid (E.2/E.2) <sup>1</sup>		Thyroid nodules (E.3/E.3) <sup>1</sup>		Thyroid enlargement (E.4/E.4) <sup>1</sup>		Diabetes-diet (E.5/E.5) <sup>1</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
		25-29	185	6	3.3	20	10.8	6	3.2	5	2.7	4	2.2
		30-34	139	4	2.9	16	11.6	5	3.6	4	2.9	1	0.7
		35+	92	.	.	7	7.6	1	1.1	3	3.3	2	2.2
	Years since diagnosis	5-9	82	1	1.2	4	4.9	.	.	.	.	1	1.2
		10-14	233	2	0.9	22	9.5	1	0.4	5	2.2	1	0.4
		15-19	259	7	2.7	18	7.0	4	1.6	6	2.3	3	1.2
		20+	233	4	1.7	33	14.3	11	4.7	11	4.7	3	1.3
	Age at diagnosis	<1	72	.	.	3	4.2	1	1.4	1	1.4	1	1.4
		1-4	230	4	1.8	22	9.6	6	2.6	9	4.0	.	.
		5-9	173	3	1.8	27	15.8	4	2.3	5	2.9	2	1.2
		10-14	160	5	3.1	14	8.8	3	1.9	3	1.9	1	0.6
		15-20	172	2	1.2	11	6.4	2	1.2	4	2.3	4	2.3
	Treatment	Surgery only	97	.	.	2	2.1	.	.	1	1.0	.	.
		Chemotherapy, no radiation	148	1	0.7	3	2.1	2	1.4	2	1.4	2	1.4
		Radiation, no chemotherapy	31	1	3.2	3	9.7	1	3.2	.	.	.	.
		Chemotherapy and radiation	450	11	2.5	63	14.1	12	2.7	18	4.0	3	0.7
		Unknown	81	1	1.2	6	7.4	1	1.2	1	1.2	3	3.7

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included

				Diabetes-pills (E.6/E.6) <sup>1</sup>		Diabetes-insulin (E.7/E.7) <sup>1</sup>		Growth hormone deficiency (E.8/E.8) <sup>1</sup>		Osteoporosis (E.10/E.10) <sup>1</sup>		Any hormonal problem <sup>2</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
		25-29	185	1	0.6	3	1.6	14	7.9	12	6.5	46	25.7
		30-34	139	.	.	3	2.2	3	2.2	5	3.6	29	21.0
		35+	92	1	1.1	2	2.2	1	1.1	5	5.5	16	17.6
	Years since diagnosis	5-9	82	.	.	.	.	7	8.6	2	2.4	12	15.0
		10-14	233	.	.	2	0.9	26	11.4	15	6.5	51	22.6
		15-19	259	1	0.4	1	0.4	23	9.1	13	5.1	56	22.0
		20+	233	1	0.4	5	2.1	19	8.3	12	5.2	61	26.8
	Age at diagnosis	<1	72	.	.	1	1.4	2	2.9	1	1.4	6	8.7
		1-4	230	.	.	.	.	41	18.2	12	5.3	64	28.7
		5-9	173	.	.	2	1.2	28	16.5	15	8.8	54	32.1
		10-14	160	1	0.6	1	0.6	3	1.9	7	4.4	30	19.0
		15-20	172	1	0.6	4	2.3	1	0.6	7	4.1	26	15.3
	Treatment	Surgery only	97	.	.	.	.	.	.	1	1.0	4	4.2
		Chemotherapy, no radiation	148	.	.	2	1.4	.	.	3	2.1	10	6.9
		Radiation, no chemotherapy	31	.	.	1	3.2	1	3.6	.	.	6	20.0
		Chemotherapy and radiation	450	1	0.2	3	0.7	71	16.1	29	6.5	142	32.6
		Unknown	81	1	1.2	2	2.5	3	3.7	9	11.1	18	22.2

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included



				Overactive thyroid (E.1/E.1) <sup>1</sup>		Underactive thyroid (E.2/E.2) <sup>1</sup>		Thyroid nodules (E.3/E.3) <sup>1</sup>		Thyroid enlargement (E.4/E.4) <sup>1</sup>		Diabetes-diet (E.5/E.5) <sup>1</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		2098	22	1.1	71	3.4	34	1.6	37	1.8	21	1.0
	Age at baseline	<18	96	.	.	2	2.1	.	.	.	.	.	.
		18-19	72	.	.	.	.	.	.	1	1.4	.	.
		20-24	388	2	0.5	12	3.1	5	1.3	5	1.3	4	1.0
		25-29	568	5	0.9	17	3.0	6	1.1	11	2.0	3	0.5
		30-34	566	8	1.4	25	4.4	11	2.0	9	1.6	7	1.2
		35+	408	7	1.7	15	3.7	12	2.9	11	2.7	7	1.7
	Years since diagnosis	5-9	241	1	0.4	5	2.1	.	.	3	1.3	.	.
		10-14	681	6	0.9	23	3.4	7	1.0	10	1.5	7	1.0
		15-19	676	7	1.0	21	3.1	12	1.8	12	1.8	6	0.9
		20+	500	8	1.6	22	4.4	15	3.0	12	2.4	8	1.6
	Age at diagnosis	<1	9	.	.	.	.	.	.	.	.	.	.
		1-4	88	1	1.2	5	5.9	3	3.5	1	1.2	.	.
		5-9	371	.	.	10	2.7	4	1.1	5	1.4	3	0.8
		10-14	840	13	1.6	28	3.3	13	1.5	13	1.6	10	1.2
		15-20	790	8	1.0	28	3.6	14	1.8	18	2.3	8	1.0
	Treatment	Surgery only	119	2	1.7	2	1.7	1	0.8	2	1.7	1	0.8
		Chemotherapy, no radiation	1189	13	1.1	38	3.2	21	1.8	27	2.3	16	1.4
		Radiation, no chemotherapy	17	.	.	2	11.8	1	5.9	1	5.9	.	.
		Chemotherapy and radiation	580	5	0.9	24	4.1	8	1.4	5	0.9	3	0.5
		Unknown	193	2	1.0	5	2.6	3	1.6	2	1.0	1	0.5
Males	All cases		1084	10	0.9	15	1.4	10	0.9	11	1.0	5	0.5
	Age at baseline	<18	48	.	.	1	2.1	.	.	.	.	.	.
		18-19	36	.	.	.	.	.	.	.	.	.	.
		20-24	193	1	0.5	1	0.5	2	1.0	1	0.5	.	.
		25-29	299	2	0.7	6	2.0	3	1.0	4	1.4	.	.
		30-34	283	4	1.4	5	1.8	1	0.4	3	1.1	3	1.1
		35+	225	3	1.3	2	0.9	4	1.8	3	1.3	2	0.9
	Years since diagnosis	5-9	132	.	.	1	0.8	.	.	1	0.8	.	.
		10-14	349	4	1.1	5	1.4	3	0.9	4	1.2	1	0.3
		15-19	347	2	0.6	5	1.4	2	0.6	3	0.9	2	0.6
		20+	256	4	1.6	4	1.6	5	2.0	3	1.2	2	0.8
	Age at diagnosis	<1	4	.	.	.	.	.	.	.	.	.	.
		1-4	47	1	2.2	2	4.3	2	4.3	.	.	.	.
		5-9	190	.	.	3	1.6	1	0.5	1	0.5	1	0.5
		10-14	401	3	0.8	4	1.0	2	0.5	3	0.8	.	.
		15-20	442	6	1.4	6	1.4	5	1.1	7	1.6	4	0.9
	Treatment	Surgery only	48	2	4.2	1	2.1	1	2.1	2	4.3	.	.
		Chemotherapy, no radiation	611	5	0.8	7	1.1	4	0.7	7	1.2	5	0.8
		Radiation, no chemotherapy	9	.	.	2	22.2	1	11.1	1	11.1	.	.
		Chemotherapy and radiation	296	2	0.7	4	1.4	3	1.0	1	0.3	.	.
		Unknown	120	1	0.8	1	0.8	1	0.8	.	.	.	.
Females	All cases		1014	12	1.2	56	5.6	24	2.4	26	2.6	16	1.6
	Age at baseline	<18	48	.	.	1	2.1	.	.	.	.	.	.
		18-19	36	.	.	.	.	.	.	1	2.8	.	.
		20-24	195	1	0.5	11	5.7	3	1.5	4	2.1	4	2.1

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems

n=7 participants with no baseline information are not included

				Diabetes-pills (E.6/E.6) <sup>1</sup>		Diabetes-insulin (E.7/E.7) <sup>1</sup>		Growth hormone deficiency (E.8/E.8) <sup>1</sup>		Osteoporosis (E.10/E.10) <sup>1</sup>		Any hormonal problem <sup>2</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		2098	19	0.9	19	0.9	26	1.3	123	5.9	279	13.7
	Age at baseline	<18	96	.	.	1	1.1	5	5.3	5	5.3	12	12.6
		18-19	72	.	.	.	.	2	2.8	3	4.2	5	7.1
		20-24	388	3	0.8	2	0.5	9	2.4	26	6.7	49	13.0
		25-29	568	2	0.4	4	0.7	4	0.7	30	5.3	67	12.2
		30-34	566	8	1.4	7	1.2	4	0.7	37	6.6	87	15.9
		35+	408	6	1.5	5	1.2	2	0.5	22	5.4	59	14.6
	Years since diagnosis	5-9	241	1	0.4	1	0.4	3	1.3	10	4.1	20	8.7
		10-14	681	4	0.6	5	0.7	9	1.3	38	5.6	86	13.0
		15-19	676	9	1.3	7	1.0	7	1.0	37	5.5	86	13.0
		20+	500	5	1.0	6	1.2	7	1.4	38	7.7	87	17.8
	Age at diagnosis	<1	9	.	.	.	.	2	22.2	1	11.1	2	22.2
		1-4	88	.	.	.	.	6	7.1	6	7.1	17	20.0
		5-9	371	2	0.5	2	0.5	8	2.2	26	7.0	45	12.4
		10-14	840	10	1.2	9	1.1	8	1.0	49	5.9	113	13.8
		15-20	790	7	0.9	8	1.0	2	0.3	41	5.2	102	13.3
	Treatment	Surgery only	119	.	.	3	2.5	.	.	2	1.7	9	7.9
		Chemotherapy, no radiation	1189	17	1.5	12	1.0	5	0.4	63	5.3	151	13.1
		Radiation, no chemotherapy	17	.	.	.	.	1	5.9	.	.	3	17.6
		Chemotherapy and radiation	580	2	0.4	4	0.7	17	3.0	51	8.8	96	17.0
		Unknown	193	.	.	.	.	3	1.6	7	3.6	20	10.4
Males	All cases		1084	4	0.4	9	0.8	11	1.0	40	3.7	96	9.1
	Age at baseline	<18	48	.	.	1	2.1	3	6.3	2	4.2	7	14.6
		18-19	36	.	.	.	.	.	.	2	5.6	2	5.7
		20-24	193	.	.	1	0.5	2	1.1	6	3.1	13	7.0
		25-29	299	.	.	1	0.3	2	0.7	11	3.7	26	9.1
		30-34	283	2	0.7	2	0.7	3	1.1	10	3.6	25	9.1
		35+	225	2	0.9	4	1.8	1	0.4	9	4.0	23	10.3
	Years since diagnosis	5-9	132	.	.	1	0.8	1	0.8	3	2.3	7	5.6
		10-14	349	.	.	2	0.6	3	0.9	13	3.7	31	9.2
		15-19	347	3	0.9	2	0.6	4	1.2	11	3.2	29	8.6
		20+	256	1	0.4	4	1.6	3	1.2	13	5.1	29	11.5
	Age at diagnosis	<1	4	.	.	.	.	1	25.0	.	.	1	25.0
		1-4	47	.	.	.	.	2	4.3	3	6.5	8	17.4
		5-9	190	1	0.5	.	.	4	2.1	7	3.7	15	8.1
		10-14	401	1	0.3	4	1.0	2	0.5	15	3.8	30	7.7
		15-20	442	2	0.5	5	1.1	2	0.5	15	3.4	42	9.8
	Treatment	Surgery only	48	.	.	2	4.2	.	.	2	4.2	7	14.9
		Chemotherapy, no radiation	611	4	0.7	4	0.7	3	0.5	19	3.1	48	8.1
		Radiation, no chemotherapy	9	.	.	.	.	1	11.1	.	.	3	33.3
		Chemotherapy and radiation	296	.	.	3	1.0	6	2.1	16	5.4	32	11.2
		Unknown	120	.	.	.	.	1	0.8	3	2.5	6	5.0
Females	All cases		1014	15	1.5	10	1.0	15	1.5	83	8.2	183	18.5
	Age at baseline	<18	48	.	.	.	.	2	4.3	3	6.4	5	10.6
		18-19	36	.	.	.	.	2	5.6	1	2.8	3	8.6
		20-24	195	3	1.6	1	0.5	7	3.6	20	10.3	36	18.9

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included

				Overactive thyroid (E.1/E.1) <sup>1</sup>		Underactive thyroid (E.2/E.2) <sup>1</sup>		Thyroid nodules (E.3/E.3) <sup>1</sup>		Thyroid enlargement (E.4/E.4) <sup>1</sup>		Diabetes-diet (E.5/E.5) <sup>1</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
		25-29	269	3	1.1	11	4.1	3	1.1	7	2.6	3	1.1
		30-34	283	4	1.4	20	7.1	10	3.5	6	2.1	4	1.4
		35+	183	4	2.2	13	7.1	8	4.4	8	4.4	5	2.7
	Years since diagnosis	5-9	109	1	0.9	4	3.7	.	.	2	1.9	.	.
		10-14	332	2	0.6	18	5.5	4	1.2	6	1.8	6	1.8
		15-19	329	5	1.5	16	4.9	10	3.0	9	2.8	4	1.2
		20+	244	4	1.6	18	7.4	10	4.1	9	3.7	6	2.5
	Age at diagnosis	<1	5	.	.	.	.	.	.	.	.	.	.
		1-4	41	.	.	3	7.7	1	2.6	1	2.6	.	.
		5-9	181	.	.	7	3.9	3	1.7	4	2.2	2	1.1
		10-14	439	10	2.3	24	5.5	11	2.5	10	2.3	10	2.3
		15-20	348	2	0.6	22	6.3	9	2.6	11	3.2	4	1.2
	Treatment	Surgery only	71	.	.	1	1.4	.	.	.	.	1	1.4
		Chemotherapy, no radiation	578	8	1.4	31	5.4	17	3.0	20	3.5	11	1.9
		Radiation, no chemotherapy	8	.	.	.	.	.	.	.	.	.	.
		Chemotherapy and radiation	284	3	1.1	20	7.0	5	1.8	4	1.4	3	1.1
		Unknown	73	1	1.4	4	5.5	2	2.7	2	2.7	1	1.4

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included

				Diabetes- pills (E.6/E.6) <sup>1</sup>		Diabetes- insulin (E.7/E.7) <sup>1</sup>		Growth hormone deficiency (E.8/E.8) <sup>1</sup>		Osteoporosis (E.10/E.10) <sup>1</sup>		Any hormonal problem <sup>2</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
		25-29	269	2	0.8	3	1.1	2	0.8	19	7.1	41	15.6
		30-34	283	6	2.2	5	1.8	1	0.4	27	9.6	62	22.8
		35+	183	4	2.2	1	0.5	1	0.6	13	7.1	36	20.0
	Years since diagnosis	5-9	109	1	1.0	.	.	2	1.9	7	6.4	13	12.3
		10-14	332	4	1.2	3	0.9	6	1.8	25	7.6	55	17.0
		15-19	329	6	1.8	5	1.5	3	0.9	26	8.0	57	17.8
		20+	244	4	1.7	2	0.8	4	1.7	25	10.3	58	24.6
	Age at diagnosis	<1	5	.	.	.	.	1	20.0	1	20.0	1	20.0
		1-4	41	.	.	.	.	4	10.3	3	7.7	9	23.1
		5-9	181	1	0.6	2	1.1	4	2.2	19	10.6	30	16.9
		10-14	439	9	2.1	5	1.1	6	1.4	34	7.8	83	19.4
		15-20	348	5	1.5	3	0.9	.	.	26	7.5	60	17.8
	Treatment	Surgery only	71	.	.	1	1.4	.	.	.	.	2	3.0
		Chemotherapy, no radiation	578	13	2.3	8	1.4	2	0.4	44	7.7	103	18.4
		Radiation, no chemotherapy	8	.	.	.	.	.	.	.	.	.	.
		Chemotherapy and radiation	284	2	0.7	1	0.4	11	3.9	35	12.3	64	22.9
		Unknown	73	.	.	.	.	2	2.7	4	5.5	14	19.2

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included

				Overactive thyroid (E.1/E.1) <sup>1</sup>		Underactive thyroid (E.2/E.2) <sup>1</sup>		Thyroid nodules (E.3/E.3) <sup>1</sup>		Thyroid enlargement (E.4/E.4) <sup>1</sup>		Diabetes-diet (E.5/E.5) <sup>1</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		738	8	1.1	28	3.8	12	1.6	9	1.2	3	0.4
	Age at baseline	<18	61	.	.	.	.	.	.	.	.	.	.
		18-19	36	.	.	.	.	.	.	1	2.8	.	.
		20-24	170	1	0.6	5	3.0	3	1.8	2	1.2	2	1.2
		25-29	204	3	1.5	5	2.5	2	1.0	2	1.0	.	.
		30-34	164	3	1.8	13	7.9	1	0.6	1	0.6	.	.
		35+	103	1	1.0	5	4.9	6	5.8	3	2.9	1	1.0
	Years since diagnosis	5-9	103	.	.	1	1.0	.	.	2	2.0	.	.
		10-14	247	3	1.2	6	2.4	1	0.4	1	0.4	2	0.8
		15-19	223	4	1.8	9	4.0	5	2.2	3	1.3	.	.
		20+	165	1	0.6	12	7.4	6	3.7	3	1.8	1	0.6
	Age at diagnosis	<1	5	.	.	.	.	.	.	.	.	.	.
		1-4	54	.	.	2	3.8	2	3.8	1	1.9	.	.
		5-9	185	.	.	6	3.3	3	1.6	2	1.1	1	0.5
		10-14	277	6	2.2	9	3.2	2	0.7	2	0.7	1	0.4
		15-20	217	2	0.9	11	5.1	5	2.3	4	1.9	1	0.5
	Treatment	Surgery only	1	.	.	.	.	.	.	.	.	.	.
		Chemotherapy, no radiation	210	1	0.5	7	3.4	3	1.4	3	1.4	1	0.5
		Radiation, no chemotherapy	2	.	.	.	.	.	.	.	.	.	.
		Chemotherapy and radiation	461	5	1.1	19	4.1	7	1.5	5	1.1	2	0.4
		Unknown	64	2	3.1	2	3.1	2	3.1	1	1.6	.	.
Males	All cases		385	4	1.0	6	1.6	4	1.0	2	0.5	1	0.3
	Age at baseline	<18	27	.	.	.	.	.	.	.	.	.	.
		18-19	20	.	.	.	.	.	.	.	.	.	.
		20-24	87	1	1.1	.	.	1	1.1	.	.	.	.
		25-29	105	.	.	2	1.9	1	1.0	1	1.0	.	.
		30-34	90	2	2.2	3	3.3	.	.	1	1.1	.	.
		35+	56	1	1.8	1	1.8	2	3.6	.	.	1	1.8
	Years since diagnosis	5-9	55	.	.	.	.	.	.	1	1.8	.	.
		10-14	121	1	0.8	.	.	.	.	1	0.8	.	.
		15-19	122	2	1.6	3	2.5	2	1.6	.	.	.	.
		20+	87	1	1.2	3	3.5	2	2.3	.	.	1	1.2
	Age at diagnosis	<1	2	.	.	.	.	.	.	.	.	.	.
		1-4	29	.	.	.	.	1	3.6	.	.	.	.
		5-9	92	.	.	3	3.3	1	1.1	.	.	.	.
		10-14	146	3	2.1	1	0.7	1	0.7	.	.	.	.
		15-20	116	1	0.9	2	1.7	1	0.9	2	1.7	1	0.9
	Treatment	Chemotherapy, no radiation	111	1	0.9	2	1.8	.	.	1	0.9	1	0.9
		Radiation, no chemotherapy	1	.	.	.	.	.	.	.	.	.	.
		Chemotherapy and radiation	236	2	0.9	4	1.7	3	1.3	1	0.4	.	.
		Unknown	37	1	2.7	.	.	1	2.7	.	.	.	.
Females	All cases		353	4	1.1	22	6.3	8	2.3	7	2.0	2	0.6
	Age at baseline	<18	34	.	.	.	.	.	.	.	.	.	.
		18-19	16	.	.	.	.	.	.	1	6.3	.	.
		20-24	83	.	.	5	6.1	2	2.4	2	2.5	2	2.4
		25-29	99	3	3.0	3	3.0	1	1.0	1	1.0	.	.

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems

n=7 participants with no baseline information are not included

				Diabetes-pills (E.6/E.6) <sup>1</sup>		Diabetes-insulin (E.7/E.7) <sup>1</sup>		Growth hormone deficiency (E.8/E.8) <sup>1</sup>		Osteoporosis (E.10/E.10) <sup>1</sup>		Any hormonal problem <sup>2</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		738	3	0.4	5	0.7	15	2.1	50	6.8	108	15.0
	Age at baseline	<18	61	.	.	.	.	4	6.7	3	5.0	6	10.0
		18-19	36	.	.	.	.	1	2.8	2	5.6	3	8.6
		20-24	170	.	.	1	0.6	6	3.6	12	7.1	25	15.0
		25-29	204	1	0.5	1	0.5	1	0.5	14	6.9	27	13.7
		30-34	164	2	1.3	1	0.6	3	1.9	13	8.0	30	19.0
		35+	103	.	.	2	1.9	.	.	6	5.8	17	16.7
	Years since diagnosis	5-9	103	.	.	.	.	3	3.0	4	3.9	9	8.9
		10-14	247	1	0.4	2	0.8	6	2.5	16	6.5	33	13.8
		15-19	223	2	0.9	1	0.4	2	0.9	13	5.9	29	13.4
		20+	165	.	.	2	1.2	4	2.4	17	10.4	37	22.8
	Age at diagnosis	<1	5	.	.	.	.	1	20.0	1	20.0	1	20.0
		1-4	54	.	.	.	.	3	5.8	4	7.7	10	19.2
		5-9	185	.	.	.	.	6	3.3	16	8.6	27	14.9
		10-14	277	1	0.4	2	0.7	5	1.8	18	6.5	40	14.8
		15-20	217	2	0.9	3	1.4	.	.	11	5.1	30	14.3
	Treatment	Surgery only	1	.	.	.	.	.	.	.	.	.	.
		Chemotherapy, no radiation	210	2	1.0	3	1.4	.	.	5	2.4	18	8.9
		Radiation, no chemotherapy	2	.	.	.	.	.	.	.	.	.	.
		Chemotherapy and radiation	461	1	0.2	2	0.4	13	2.9	41	8.9	79	17.6
		Unknown	64	.	.	.	.	2	3.1	4	6.3	11	17.2
Males	All cases		385	.	.	4	1.0	5	1.3	14	3.7	36	9.6
	Age at baseline	<18	27	.	.	.	.	2	7.4	1	3.7	3	11.1
		18-19	20	.	.	.	.	.	.	1	5.0	1	5.0
		20-24	87	.	.	1	1.1	1	1.1	2	2.3	6	6.9
		25-29	105	.	.	1	1.0	.	.	5	4.8	9	9.1
		30-34	90	.	.	.	.	2	2.2	3	3.4	10	11.5
		35+	56	.	.	2	3.6	.	.	2	3.6	7	12.7
	Years since diagnosis	5-9	55	.	.	.	.	1	1.9	1	1.8	3	5.6
		10-14	121	.	.	2	1.7	1	0.8	3	2.5	8	6.8
		15-19	122	.	.	.	.	1	0.8	5	4.1	12	10.2
		20+	87	.	.	2	2.3	2	2.3	5	5.8	13	15.3
	Age at diagnosis	<1	2	.	.	.	.	.	.	.	.	.	.
		1-4	29	.	.	.	.	1	3.6	2	7.1	4	14.3
		5-9	92	.	.	.	.	3	3.3	4	4.3	9	10.0
		10-14	146	.	.	1	0.7	1	0.7	7	4.8	14	9.8
		15-20	116	.	.	3	2.6	.	.	1	0.9	9	8.0
	Treatment	Chemotherapy, no radiation	111	.	.	2	1.8	.	.	.	.	6	5.6
		Radiation, no chemotherapy	1	.	.	.	.	.	.	.	.	.	.
		Chemotherapy and radiation	236	.	.	2	0.8	5	2.2	13	5.5	27	11.8
		Unknown	37	.	.	.	.	.	.	1	2.7	3	8.1
Females	All cases		353	3	0.9	1	0.3	10	2.9	36	10.2	72	20.9
	Age at baseline	<18	34	.	.	.	.	2	6.1	2	6.1	3	9.1
		18-19	16	.	.	.	.	1	6.3	1	6.3	2	13.3
		20-24	83	.	.	.	.	5	6.1	10	12.0	19	23.8
		25-29	99	1	1.0	.	.	1	1.0	9	9.1	18	18.4

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included

				Overactive thyroid (E.1/E.1) <sup>1</sup>		Underactive thyroid (E.2/E.2) <sup>1</sup>		Thyroid nodules (E.3/E.3) <sup>1</sup>		Thyroid enlargement (E.4/E.4) <sup>1</sup>		Diabetes-diet (E.5/E.5) <sup>1</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
		30-34	74	1	1.4	10	13.5	1	1.4	.	.	.	.
		35+	47	.	.	4	8.5	4	8.5	3	6.4	.	.
	Years since diagnosis	5-9	48	.	.	1	2.1	.	.	1	2.1	.	.
		10-14	126	2	1.6	6	4.8	1	0.8	.	.	2	1.6
		15-19	101	2	2.0	6	5.9	3	3.0	3	3.0	.	.
		20+	78	.	.	9	11.5	4	5.1	3	3.8	.	.
	Age at diagnosis	<1	3	.	.	.	.	.	.	.	.	.	.
		1-4	25	.	.	2	8.3	1	4.2	1	4.2	.	.
		5-9	93	.	.	3	3.3	2	2.2	2	2.2	1	1.1
		10-14	131	3	2.3	8	6.1	1	0.8	2	1.6	1	0.8
		15-20	101	1	1.0	9	8.9	4	4.0	2	2.0	.	.
	Treatment	Surgery only	1	.	.	.	.	.	.	.	.	.	.
		Chemotherapy, no radiation	99	.	.	5	5.2	3	3.1	2	2.1	.	.
		Radiation, no chemotherapy	1	.	.	.	.	.	.	.	.	.	.
		Chemotherapy and radiation	225	3	1.3	15	6.7	4	1.8	4	1.8	2	0.9
		Unknown	27	1	3.7	2	7.4	1	3.7	1	3.7	.	.

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included

				Diabetes-pills (E.6/E.6) <sup>1</sup>		Diabetes-insulin (E.7/E.7) <sup>1</sup>		Growth hormone deficiency (E.8/E.8) <sup>1</sup>		Osteoporosis (E.10/E.10) <sup>1</sup>		Any hormonal problem <sup>2</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
		30-34	74	2	2.8	1	1.4	1	1.4	10	13.5	20	28.2
		35+	47	.	.	.	.	.	.	4	8.5	10	21.3
	Years since diagnosis	5-9	48	.	.	.	.	2	4.3	3	6.3	6	12.8
		10-14	126	1	0.8	.	.	5	4.0	13	10.4	25	20.7
		15-19	101	2	2.0	1	1.0	1	1.0	8	7.9	17	17.2
		20+	78	.	.	.	.	2	2.6	12	15.4	24	31.2
	Age at diagnosis	<1	3	.	.	.	.	1	33.3	1	33.3	1	33.3
		1-4	25	.	.	.	.	2	8.3	2	8.3	6	25.0
		5-9	93	.	.	.	.	3	3.3	12	12.9	18	19.8
		10-14	131	1	0.8	1	0.8	4	3.1	11	8.4	26	20.3
		15-20	101	2	2.0	.	.	.	.	10	9.9	21	21.4
	Treatment	Surgery only	1	.	.	.	.	.	.	.	.	.	.
		Chemotherapy, no radiation	99	2	2.1	1	1.0	.	.	5	5.1	12	12.6
		Radiation, no chemotherapy	1	.	.	.	.	.	.	.	.	.	.
		Chemotherapy and radiation	225	1	0.5	.	.	8	3.6	28	12.4	52	23.6
		Unknown	27	.	.	.	.	2	7.4	3	11.1	8	29.6

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'

<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included



				Overactive thyroid (E.1/E.1) <sup>1</sup>		Underactive thyroid (E.2/E.2) <sup>1</sup>		Thyroid nodules (E.3/E.3) <sup>1</sup>		Thyroid enlargement (E.4/E.4) <sup>1</sup>		Diabetes-diet (E.5/E.5) <sup>1</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		1257	14	1.1	35	2.8	21	1.7	27	2.2	17	1.4
	Age at baseline	<18	29	.	.	1	3.4	.	.	.	.	.	.
		18-19	30	.	.	.	.	.	.	.	.	.	.
		20-24	198	1	0.5	5	2.5	2	1.0	3	1.5	1	0.5
		25-29	344	2	0.6	10	2.9	4	1.2	9	2.6	3	0.9
		30-34	373	5	1.3	10	2.7	9	2.4	7	1.9	7	1.9
		35+	283	6	2.1	9	3.2	6	2.1	8	2.8	6	2.1
	Years since diagnosis	5-9	131	1	0.8	2	1.5	.	.	1	0.8	.	.
		10-14	397	3	0.8	15	3.8	5	1.3	8	2.0	5	1.3
		15-19	422	3	0.7	10	2.4	7	1.7	9	2.1	5	1.2
		20+	307	7	2.3	8	2.6	9	2.9	9	2.9	7	2.3
	Age at diagnosis	1-4	25	1	4.2	1	4.2	1	4.2	.	.	.	.
		5-9	168	.	.	3	1.8	1	0.6	3	1.8	1	0.6
		10-14	533	7	1.3	17	3.2	11	2.1	11	2.1	9	1.7
		15-20	531	6	1.1	14	2.6	8	1.5	13	2.5	7	1.3
	Treatment	Surgery only	86	2	2.3	.	.	1	1.2	2	2.3	1	1.2
		Chemotherapy, no radiation	955	12	1.3	30	3.2	18	1.9	23	2.4	15	1.6
		Radiation, no chemotherapy	10	.	.	1	10.0	1	10.0	1	10.0	.	.
		Chemotherapy and radiation	83	.	.	1	1.2	.	.	.	.	.	.
		Unknown	123	.	.	3	2.4	1	0.8	1	0.8	1	0.8
Males	All cases		647	6	0.9	7	1.1	6	0.9	8	1.2	4	0.6
	Age at baseline	<18	20	.	.	1	5.0	.	.	.	.	.	.
		18-19	12	.	.	.	.	.	.	.	.	.	.
		20-24	95	.	.	1	1.1	1	1.1	1	1.1	.	.
		25-29	183	2	1.1	3	1.6	2	1.1	3	1.7	.	.
		30-34	178	2	1.1	1	0.6	1	0.6	1	0.6	3	1.7
		35+	159	2	1.3	1	0.6	2	1.3	3	1.9	1	0.6
	Years since diagnosis	5-9	74	.	.	1	1.4	.	.	.	.	.	.
		10-14	209	3	1.4	4	1.9	3	1.4	2	1.0	1	0.5
		15-19	210	.	.	2	1.0	.	.	3	1.4	2	1.0
		20+	154	3	2.0	.	.	3	1.9	3	1.9	1	0.6
	Age at diagnosis	1-4	14	1	7.1	1	7.1	1	7.1	.	.	.	.
		5-9	84	.	.	.	.	.	.	1	1.2	1	1.2
		10-14	245	.	.	3	1.2	1	0.4	3	1.2	.	.
		15-20	304	5	1.7	3	1.0	4	1.3	4	1.3	3	1.0
	Treatment	Surgery only	30	2	6.7	.	.	1	3.3	2	6.7	.	.
		Chemotherapy, no radiation	488	4	0.8	5	1.0	4	0.8	5	1.0	4	0.8
		Radiation, no chemotherapy	6	.	.	1	16.7	1	16.7	1	16.7	.	.
		Chemotherapy and radiation	44	.	.	.	.	.	.	.	.	.	.
		Unknown	79	.	.	1	1.3	.	.	.	.	.	.
Females	All cases		610	8	1.3	28	4.6	15	2.5	19	3.1	13	2.1
	Age at baseline	<18	9	.	.	.	.	.	.	.	.	.	.
		18-19	18	.	.	.	.	.	.	.	.	.	.
		20-24	103	1	1.0	4	3.9	1	1.0	2	2.0	1	1.0
		25-29	161	.	.	7	4.4	2	1.3	6	3.8	3	1.9
		30-34	195	3	1.5	9	4.7	8	4.1	6	3.1	4	2.1

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems

n=7 participants with no baseline information are not included

				Diabetes-pills (E.6/E.6) <sup>1</sup>		Diabetes-insulin (E.7/E.7) <sup>1</sup>		Growth hormone deficiency (E.8/E.8) <sup>1</sup>		Osteoporosis (E.10/E.10) <sup>1</sup>		Any hormonal problem <sup>2</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
<b>Both sexes</b>	<b>All cases</b>		<b>1257</b>	<b>15</b>	<b>1.2</b>	<b>13</b>	<b>1.0</b>	<b>7</b>	<b>0.6</b>	<b>67</b>	<b>5.4</b>	<b>154</b>	<b>12.6</b>
	<b>Age at baseline</b>	<18	29	.	.	1	3.4	.	.	2	6.9	4	13.8
		18-19	30	.	.	.	.	.	.	.	.	.	.
		20-24	198	2	1.0	.	.	2	1.0	14	7.1	22	11.5
		25-29	344	1	0.3	3	0.9	2	0.6	16	4.7	38	11.4
		30-34	373	6	1.6	6	1.6	1	0.3	22	6.0	52	14.4
		35+	283	6	2.1	3	1.1	2	0.7	13	4.6	38	13.6
	<b>Years since diagnosis</b>	5-9	131	1	0.8	1	0.8	.	.	6	4.6	9	7.3
		10-14	397	3	0.8	3	0.8	2	0.5	20	5.1	47	12.1
		15-19	422	6	1.4	5	1.2	3	0.7	23	5.5	53	12.8
		20+	307	5	1.6	4	1.3	2	0.7	18	5.9	45	15.1
	<b>Age at diagnosis</b>	1-4	25	.	.	.	.	1	4.2	1	4.2	3	12.5
		5-9	168	1	0.6	1	0.6	1	0.6	10	6.0	17	10.3
		10-14	533	9	1.7	7	1.3	3	0.6	30	5.7	70	13.5
		15-20	531	5	1.0	5	0.9	2	0.4	26	4.9	64	12.4
	<b>Treatment</b>	Surgery only	86	.	.	3	3.5	.	.	2	2.3	7	8.4
		Chemotherapy, no radiation	955	15	1.6	9	0.9	5	0.5	58	6.1	131	14.1
		Radiation, no chemotherapy	10	.	.	.	.	.	.	.	.	2	20.0
		Chemotherapy and radiation	83	.	.	1	1.2	1	1.2	4	4.8	5	6.2
		Unknown	123	.	.	.	.	1	0.8	3	2.4	9	7.3
<b>Males</b>	<b>All cases</b>		<b>647</b>	<b>4</b>	<b>0.6</b>	<b>5</b>	<b>0.8</b>	<b>4</b>	<b>0.6</b>	<b>23</b>	<b>3.6</b>	<b>53</b>	<b>8.4</b>
	<b>Age at baseline</b>	<18	20	.	.	1	5.0	.	.	1	5.0	3	15.0
		18-19	12	.	.	.	.	.	.	.	.	.	.
		20-24	95	.	.	.	.	1	1.1	4	4.2	7	7.8
		25-29	183	.	.	.	.	1	0.6	6	3.3	16	9.0
		30-34	178	2	1.1	2	1.1	1	0.6	7	4.0	13	7.5
		35+	159	2	1.3	2	1.3	1	0.6	5	3.1	14	8.8
	<b>Years since diagnosis</b>	5-9	74	.	.	1	1.4	.	.	2	2.7	4	5.9
		10-14	209	.	.	.	.	1	0.5	9	4.3	19	9.4
		15-19	210	3	1.4	2	1.0	3	1.4	6	2.9	17	8.2
		20+	154	1	0.6	2	1.3	.	.	6	3.9	13	8.5
	<b>Age at diagnosis</b>	1-4	14	.	.	.	.	.	.	.	.	2	14.3
		5-9	84	1	1.2	.	.	1	1.2	3	3.6	6	7.3
		10-14	245	1	0.4	3	1.2	1	0.4	8	3.3	16	6.7
		15-20	304	2	0.7	2	0.7	2	0.7	12	4.0	29	9.8
	<b>Treatment</b>	Surgery only	30	.	.	2	6.7	.	.	2	6.7	6	20.0
		Chemotherapy, no radiation	488	4	0.8	2	0.4	3	0.6	19	3.9	41	8.6
		Radiation, no chemotherapy	6	.	.	.	.	.	.	.	.	2	33.3
		Chemotherapy and radiation	44	.	.	1	2.3	.	.	.	.	1	2.4
		Unknown	79	.	.	.	.	1	1.3	2	2.5	3	3.8
<b>Females</b>	<b>All cases</b>		<b>610</b>	<b>11</b>	<b>1.8</b>	<b>8</b>	<b>1.3</b>	<b>3</b>	<b>0.5</b>	<b>44</b>	<b>7.3</b>	<b>101</b>	<b>17.0</b>
	<b>Age at baseline</b>	<18	9	.	.	.	.	.	.	1	11.1	1	11.1
		18-19	18	.	.	.	.	.	.	.	.	.	.
		20-24	103	2	2.0	.	.	1	1.0	10	9.7	15	14.9
		25-29	161	1	0.6	3	1.9	1	0.6	10	6.3	22	14.1
		30-34	195	4	2.1	4	2.1	.	.	15	7.8	39	20.7

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems

n=7 participants with no baseline information are not included

				Overactive thyroid (E.1/E.1) <sup>1</sup>		Underactive thyroid (E.2/E.2) <sup>1</sup>		Thyroid nodules (E.3/E.3) <sup>1</sup>		Thyroid enlargement (E.4/E.4) <sup>1</sup>		Diabetes-diet (E.5/E.5) <sup>1</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
		35+	124	4	3.2	8	6.5	4	3.2	5	4.0	5	4.1
	Years since diagnosis	5-9	57	1	1.8	1	1.8	.	.	1	1.8	.	.
		10-14	188	.	.	11	5.9	2	1.1	6	3.2	4	2.1
		15-19	212	3	1.4	8	3.8	7	3.3	6	2.9	3	1.4
		20+	153	4	2.6	8	5.3	6	3.9	6	3.9	6	4.0
	Age at diagnosis	1-4	11	.	.	.	.	.	.	.	.	.	.
		5-9	84	.	.	3	3.6	1	1.2	2	2.4	.	.
		10-14	288	7	2.4	14	4.9	10	3.5	8	2.8	9	3.1
		15-20	227	1	0.4	11	4.9	4	1.8	9	4.0	4	1.8
	Treatment	Surgery only	56	.	.	.	.	.	.	.	.	1	1.8
		Chemotherapy, no radiation	467	8	1.7	25	5.4	14	3.0	18	3.9	11	2.4
		Radiation, no chemotherapy	4	.	.	.	.	.	.	.	.	.	.
		Chemotherapy and radiation	39	.	.	1	2.6	.	.	.	.	.	.
		Unknown	44	.	.	2	4.5	1	2.3	1	2.3	1	2.3

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'

<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
 n=7 participants with no baseline information are not included

				Diabetes- pills (E.6/E.6) <sup>1</sup>		Diabetes- insulin (E.7/E.7) <sup>1</sup>		Growth hormone deficiency (E.8/E.8) <sup>1</sup>		Osteoporosis (E.10/E.10) <sup>1</sup>		Any hormonal problem <sup>2</sup>	
			All cases	N	%	N	%	N	%	N	%	N	%
		35+	124	4	3.2	1	0.8	1	0.8	8	6.5	24	19.8
	Years since diagnosis	5-9	57	1	1.9	.	.	.	.	4	7.0	5	9.1
		10-14	188	3	1.6	3	1.6	1	0.5	11	5.9	28	15.1
		15-19	212	3	1.4	3	1.4	.	.	17	8.1	36	17.4
		20+	153	4	2.6	2	1.3	2	1.4	12	7.9	32	21.9
	Age at diagnosis	1-4	11	.	.	.	.	1	10.0	1	10.0	1	10.0
		5-9	84	.	.	1	1.2	.	.	7	8.4	11	13.3
		10-14	288	8	2.8	4	1.4	2	0.7	22	7.7	54	19.4
		15-20	227	3	1.3	3	1.3	.	.	14	6.2	35	15.8
	Treatment	Surgery only	56	.	.	1	1.8	.	.	.	.	1	1.9
		Chemotherapy, no radiation	467	11	2.4	7	1.5	2	0.4	39	8.4	90	19.9
		Radiation, no chemotherapy	4	.	.	.	.	.	.	.	.	.	.
		Chemotherapy and radiation	39	.	.	.	.	1	2.6	4	10.3	4	10.3
		Unknown	44	.	.	.	.	.	.	1	2.3	6	13.6

CCSS data from Jan2020 data freeze

<sup>1</sup> N and % based on response of 'Yes'<sup>2</sup> 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems  
n=7 participants with no baseline information are not included